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ABSTRACT 
 
ROBUST BIOSENSORS FOR HEALTHCARE APPLICATIONS: FROM HIGH-
CONTENT SCREENING TO POINT-OF-CARE TESTING 
 
SEPTEMBER 2017 
NGOC D. B. LE 
B.S., SHORTER UNIVERSITY 
Ph.D., UNIVERSITY OF MASSACHUSETTS AMHERST 
Directed by: Professor Vincent M. Rotello 
 
Efficient detection of proteins, mammalian cells, microorganisms and other 
biological systems in complex mixture is essential in disease diagnosis and 
environmental health. Therefore, technological platforms that provide sensors of high 
sensitivity, selectivity and stability are greatly desired. Recently, the ‘chemical-nose’ 
sensing approach has proved to be an effective strategy for profiling bio-relevant targets 
in complex mixtures. Detecting analytes in complex mixture is a challenge that 
conventional specificity-based sensors are still trying to solve due to the requirement of 
prior knowledge of the analyte, which is unknown in many cases. This thesis focuses on 
how to develop simple and robust chemical-nose sensors for complex mixtures using 
supramolecular interactions between nanoparticles, fluorescent proteins, enzymes, and 
fluorescent polymers. We have successfully developed effective sensors for many 
healthcare applications including chemotherapeutic drug profiling, cancer diagnostics, 
environmental toxicity and bacterial detection. Throughout this dissertation, there is an 
emphasis on moving from high-content screening to point-of-care testing, especially in 
 viii 
cancer diagnostics. Overall, the chemical-nose sensors provide a simple generic tool for 
bio-relevant analyte profiling, avoiding additional processing steps prior to screening as 
seen in traditional methods. More importantly, chemical-nose sensors hold great promise 
for addressing the needs in personalized screening of disease states and environmental 
toxicology. 
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 1 
CHAPTER 1 
 
INTRODUCTION 
 
1.1.  Biosensor 
 
Efficient detection of proteins, mammalian cells, microorganisms and other 
biological systems in complex mixture is essential in disease diagnosis, forensic, 
agricultural, and environmental toxicity. Early detection of diseases or identification of 
harmful chemicals in the environment provide the prospect of better health and alarm 
people to take appropriate actions in a timely manner. Therefore, technological platforms 
that provide sensors of high sensitivity, selectivity and stability are in high demand. 
Biosensors have two functional components: recognition elements and 
transducers. Recognition elements are receptors used to recognize and bind to the target 
analytes. This interaction between the analyte and the receptor is designed to produce an 
effect that can be measured by a transducer. Receptors can be biological species, such as 
antibodies, enzymes, proteins, nucleic acid, or synthetic elements such as small 
molecules, nanoparticles, and polymers. To transduce the analyte-receptor binding event, 
a number of techniques are available including 1) optical (absorption, luminescence, 
fluorescence, and surface plasmon resonance), 2) electrochemical, and 3) mass-sensitive 
measurements (surface acoustic wave and microbalance).  
The efficiency of a biosensor is critically related to the outcome of each process 
associating with each component, recognition and transducer, in term of the response 
time, signal-to-noise (S/N) characteristics, sensitivity, and selectivity of the system. Thus, 
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much attention in the field has been focusing on improving the recognition process as 
well as designing new signal transduction mechanisms. With the advent of nanostructures 
and new interface materials, the pursuit of new recognition and transduction processes is 
made possible for the development of novel biosensors.  
 
1.2.  Biosensor designs: Lock-and-key specificity versus chemical-nose selectivity 
 
Biosensors can be broadly split into two types of sensing designs: highly specific 
sensing (lock-and-key approach), and array-based selective sensing (chemical-nose 
approach). The former is a sensor that in its strict definition would be completely specific 
to a single analyte and not recognize any other targets. In this context, the receptor is the 
lock and the analyte is the key.  The notion leads to the concept of one key that is 
complementary to one lock, thereby opening up only one lock, recognizing only one 
target. This idea is approached by antibodies, lectins, aptamers and enzymes. As an 
example for using an antibody in identifying and capturing a target analyte, Sha and 
coworkers developed a sensor for cancer circulating cells (CTCs). This sensor was 
fabricated by combining capturing capability of a magnetic bead and specific labeling of 
surface enhanced Raman scattering (SERS) nanotags.1 This bead was conjugated with 
anti-EpCAM antibody to capture SKBR3 cancer cells. These cells were then labeled for 
SERS detection by gold nanoparticles (AuNPs) functionalized with anti-HER2 antibody 
(human epidermal growth factor receptor-2) (Figure 1.1).2 In a similar study, SERS-based 
systems were further employed for in vivo tumor targeting.3  
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Figure 1.1. Schematic illustration of the immuno-complex formed by nanoplex biotags 
and magnetic bead conjugates binding to the model tumor cell. Republished with 
permission from ref. 1. 
 
 
There are several advantages when using the lock-and-key approach such as the 
absence of false positive results and an ultrasensitive detection.4 However, since specific 
recognition-based sensors require pre-identification of the biomarkers, they face certain 
limitations when the analytes are unknown and/or their structures are not fully 
characterized. In that case, detecting unknown analytes using lock-and-key sensing 
approach is impractical. In addition, even when the biomarker is known, the specific 
sensing approach would not be an ideal test for systems that contain multiple analytes 
with varied biomarker levels among cell populations. For example, cancer cells present 
multiple biomarkers on the cell surface and these markers coexist in normal cells at 
different levels, making the detection of a specific biomarker that is strictly associating 
with only cancer status nearly impossible. These subtle changes in the biomarker levels 
could be indicative of dramatic phenotypic differences. As an alternative, sensors using 
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selectivity-based modality do not require the knowledge of a specific biomarker. On the 
contrary, selectivity-based approaches capture the responses from complex analytes to 
generate a signature for each sample. In a typical array-based sensor, a set of recognition 
elements interacts with a number of different analytes or classes of analytes, providing a 
process reminiscent of mammalian olfaction.5 This mechanistic similarity is why array-
based sensors are often denoted as chemical ‘‘noses’’ or ‘‘tongues’’ (Figure 1.2).6  
 
Figure 1.2. Electronic nose devices mimic the human olfactory system. Adapted from 
ref. 6. 
 
 Chemical-nose sensing approach mimics the mammalian olfactory system to 
recognize mixtures of analytes. Overall, there are about 1000 genes that encode olfactory 
receptors, and each olfactory receptor has multiple sites for odorant binding with 
different affinity levels. This characteristic is known as crossreactivity.7,8 A generated 
unique signaling fingerprint for a specific odorant is then interpreted in the olfactory 
cortex by matching the signal with previously established patterns of analytes. This 
process makes it possible to distinguish between thousands of odorants using just much 
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fewer numbers of olfactory receptors (Figure 1.2). The effort of mimicking the olfactory 
system for analyte detection has led to the first model of an 'electronic nose', reported by 
Persaud and Dodd in 1982.9 Their idea was to detect different volatile compounds by 
mimicking the three different stages of the human olfactory system, including interacting 
with the odorant, establishing the pattern of the odorant, and identifing what the odorant 
is using biochemical sensors.  
 The advantage of chemical-nose sensor is that it can be trained to recognize 
complex mixtures without the knowledge of what types of biomarkers the mixture 
contains. Chemical-nose approach is useful when the disease lacks an ideal biomarker or 
biomarkers are poorly characterized such as in cancer disease. This method has been used 
to sense calcium and metal ions, pH levels, sugars as well as cholesterol levels in blood, 
cocaine in urine, and toxins in water.10,11 Chemical nose sensors can also recognize a 
wide range of volatile organic compounds,12 amino acids,13 proteins,14 carbohydrates,15 
mammalian cells.16  
One of the strengths of nose-based sensing is the versatility of the methodology. 
This versatility provides a challenge: array-based sensors need to be retrained and 
validated for each new analyte, and baseline profiles for known samples must be 
carefully examined to maximize accuracy.17 Perhaps the greatest challenge of nose type 
sensing is the fundamental difference between this method and other biomarker-based 
strategies. Just like our sense of smell, sensing using olfaction mimics is inherently 
hypothesis-free, a situation with which many researchers are not yet comfortable. In this 
dissertation, we focus on the development of chemical-nose sensors for healthcare 
applications.  
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1.3. Gold nanoparticles and fluorescent polymers as efficient receptors for chemical-
nose sensor designs 
 
Gold nanoparticles (AuNPs) possess several distinctive physical and chemical 
attributes that make them promising synthetic scaffolds for creating novel biosensor 
systems.18 First of all, the size of the NP core is tunable from 1 – 150 nm, an ideal size 
for the interaction of AuNPs with bio-relevant analytes.19 The high surface area-to-
volume ratio of AuNPs provides dense ligand loading, enhancing the interaction with 
analytes.20 These particles typically have a hydrophobic core for stability. For biological 
applications, oligo(ethylene glycol) (OEG) is added in the linker to enhance 
biocompatibility and minimize non-specific adsorption of other materials. Lastly, 
recognition receptors on the surface of AuNPs are used for the interactions with bio-
analytes. A common structure of ligands on a AuNP for biomolecular interactions is 
shown in Figure 1.3. Most importantly, AuNPs have excellent quenching ability for 
fluorophores, an ideal feature for biosensor design. 
 
 
Figure 1.3. Schematic of common surface ligands on AuNPs used for interactions with 
biological systems. The multifunctional particle monolayers featuring a hydrophobic core 
for stability, OEG layer for biocompatibility, and recognition elements on the surface for 
interaction with biomolecules. 
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The diverse ligand functionalities enabled by the ease of AuNP synthesis, along 
with unique features of AuNPs as mentioned above provide a versatile scaffold for 
constructing biosensor using chemical-nose approach. Our group has pioneered the use of 
AuNPs for chemical-nose sensing systems by non-covalently assembling AuNPs with 
different types of transducers such as fluorescent proteins (including EBFP2, EGFP, and 
td Tomato) and conjugated fluorescent polymers. In this design, cationic AuNPs with 
various functional headgroups form supramolecular complexes with anionic fluorescent 
proteins or polymers (poly(p-phenyleneethynylene) (PPE) to quench their intrinsic 
fluorescence. Competitive bindings of the bio-analytes release the fluorescent proteins or 
polymers, resulting in their fluorescence recovery.21,22 This approach has been used 
successfully for protein, cell, and tissue identification.  
Another type of receptor that is suitable for the design of chemical-nose sensor is 
fluorescent polymer. Besides the use of fluorescent polymer as transducers as described 
previously, conjugated polymers can also act as receptor to recognize bio-analytes. 
Unlike small molecules and nonconjugated polymers, these conjugated polymers are 
more responsive to conformational or environmental changes due to its unity of 
delocalized electronic structure of the polymer backbones. Such behavior of conjugated 
polymers provides more dynamic interactions (either intra- or intermolecularly) that 
could lead to various changes in the fluorescence outputs, providing a rich signature 
profile for complex analytes, a requirement for chemical-nose approach. Conjugated 
polymers can be designed to have high fluorescence quantum yields in aqueous solution 
and ability to interact electrostatically with other charged species. These water-soluble 
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polymers are also attractive because of their easily tailoring multivalent functionalities, 
stability, and scalability properties. Some of the conjugated polymers that have been used 
for chemical nose sensing are poly(p-phenyleneethynylen) (PPEs) and poly(p-
aryleneethynylene)s (PAE) for the detection of proteins, antibiotics, explosives, and fruit 
juices.23-26  
 
1.4. High-content screening: ideal space for chemical-nose sensors  
 
There is always high demand for rapid identification of mechanisms in drug 
discovery and detections of serious diseases. Thus, high-throughput screening (HTS) and 
high-content screening (HCS) have been extensively implemented to meet the demand. 
While HTS focuses on rapid examination of the effects of thousands of testing 
compounds in various in vitro and cell-based assays, HCS approaches might sacrifice 
some of the high-throughput speed to achieve more information in phenotypic 
complexity measured by the assay endpoints.  
Whole cells have been the major target for many assays and have the potential to 
provide rapid sensing with minimal processing, in contrast to approaches that need to 
physically extract cell contents such as intracellular proteins, nucleic acids, or other 
markers buried inside the cells. The rich environment presented by the cell exterior also 
gives cell sensors the capability to read out the phenotypes of cells, a property that is the 
final outcome of multiple factors including both genetic and epigenetic variations. Taking 
advantage of the final phenotypic outcome of cells, HCS uses a set of analytical methods 
such as automated microscopy, multi-parameter image processing, and visualization tools 
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to extract data from different features of cell populations. These features include spatial 
distribution of targets, individual cell and organelle morphology. For example, Young 
and coworkers have developed a HCS method to profile mechanisms of action in drug 
discovery that combines signals from multiple fluorescence probes that show cells’ 
features such as nuclear size, DNA replication, chromosome condensation, nuclear 
morphology, and nuclear ellipticity. Some of these features have obvious biological 
meaning such as the amount of DNA per nucleus. However, the biological importance of 
other features has much less obvious meaning such as the DNA texture or nuclear 
ellipticity. Biologists usually overlook these non-obvious features since they are not 
‘hypothesis-driven’ markers, even though they may contribute some valuable insights. 
The goal of HCS is to create a unique fingerprint of cell phenotypes composed of 
multiple specific cell features using various fluorescence probes. These HCS approaches 
are very powerful in profiling mechanism/cell status of interested. However, as we can 
imagine, extracting numerous cell phenotypic features through staining, fixing and 
imaging, these HCS methods face the limitation of multi-step processing of cells prior to 
analyses. There are also challenges arising from limited dynamic range, time consuming 
steps, and expensive instrumentation that restrict the applicability of these methods for 
rapid screening. 
As mentioned earlier, since chemical-nose sensor can create fingerprints for each 
analyte including all obvious and non-obvious features of cells in a very rapid manner, it 
presents an ideal method for minimizing number of cellular parameters typically found in 
HCS assays to greatly expedite drug development and disease diagnosis.  
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1.5. Chemical-nose sensors offer a new avenue for point-of-care testing  
 
Changes in healthcare delivery trend have driven the widespread of point-of-care 
testing (PoC) in disease diagnosis. This change is partly due to economic pressures and 
the general recognition that cares need to be less fragmented and more patient-centered.27 
The concept of PoC testing is aimed at delivering less costly care, closer to the patient’s 
home and not around the provider. Typically, the testing process is quite disconnected 
with the consultation process such that a patient has to deal with multiple doctor visits to 
complete the health assessment. This issue appears clearly for those who have chronic 
diseases such as diabetes where regular monitoring of glucose level by frequent blood 
test is necessary. As a result, the growth in self-monitoring of blood glucose up to date is 
the evidence for the need of more convenient and sometimes, more effective care.28,29 
 
Table 1.1. The ASSURED guidelines that indicate the features that should be designed 
into all POC testing devices. Adapted from ref. 28. 
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PoC testing can be divided into two categories: 1) small handheld devices and 2) 
larger bench-top devices. The former type usually provides qualitative or semi-
quantitative determination of analyte concentrations. Some of the dominant technologies 
are glucose biosensor strips or lateral flow strips using immobilized antibodies for 
biomarker detections such as cardiac markers and infectious pathogens.29 The second 
category includes larger devices to use in a laboratory setting but with reduced size and 
complexity. These devices are used to monitor ‘critical care’ analytes such as blood 
gases, electrolyte, and certain metabolites. Recently, molecular technique such as PCR 
was incorporated into a sufficiently small device for infectious disease testing at the point 
of care. The World Health Organization (WHO) determined desired features for PoC 
devices as listed in Table 1.1, a guideline known as ASSURED.29 Of course, some 
features might be more important than others, depending on the final end-users and 
purposes (Figure 1.4). To further improve the concept of PoC testings to include the 
parameters of end-users and test purposes that are lacking in the ASSURED guideline, a 
recent PoC concept has been developed. This concept views PoC testing as multiple 
components including 1) the complexity of technologies that ranges from simplest to 
more sophisticated, 2) users including lay persons to highly trained workers, 3) settings in 
which the test is needed including home, communities, clinics, peripheral laboratory, and 
hospital. When we separate PoC need based on diverse settings, PoC tests do not need to 
meet all the requirements listed in the ASSURED guideline. For example, malaria rapid 
diagnostic tests used by community health workers in Africa or in-home pregnancy tests 
need to be very simple, instrument-free and straightforward because the goal here is self-
assessment. At the other end of the spectrum showed in Figure 1.4, hospitals have 
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starting to implement more PoC testing programs. For example, emergency room doctors 
use handheld ultrasound devices to rapidly diagnose and treat pregnancy complications. 
Rapid tests are also being used in intensive care units to make timely decisions on patient 
treatments. In this setting of health care delivery system, tests do not need to be 
instrument-free or inexpensive. The users for these PoC tests are often well trained. 
 
Figure 1.4. The spectrum of point-of-care testing. Adapted from ref. 30 
 
The implementation of PoC devices will have tremendous healthcare and 
economic benefits, especially in developing countries where easy access to health 
providers is still limited. Looking through the lens of a global scale in both developing 
and developed countries, PoC testing will reduce the cost of disease diagnosis, improve 
survival and recovery rate of patients through more effective therapeutic treatments. This 
trait is the direct result of early detection, a blessing provided by PoC’s ease of use.  
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Despite much success in PoC testing, there are clearly areas where new PoC 
technologies are lagging behind such as in cancer and infectious disease. The challenge 
of developing PoC testing for these areas lies in the identification of an ideal biomarker. 
For example, in cancer diagnosis, the search for the ideal biomarker that only associates 
with the presence and the progress of cancer status is poorly characterized. There is a 
wide baseline of biomarker in the population, even within the subpopulation of patients 
that have the same type of cancer. This observation triggered the development of 
personalized diagnostic devices for personalized medicine via patient-specific disease 
profiling.  
Chemical-nose sensors have great potential to advance personalized medicine. 
The robustness of the system comes from the crossreactivity nature of nose sensors. They 
can be trained and retrained for any analyte, any disease status, and any specific patient 
with a simple design and no requirement of expensive and sophisticated instruments. In 
2015, a perfect example of using the nose sensor for cancer diagnosis was reported in The 
Guardian newspaper about a dog, named Frankie, who could detect thyroid cancer with 
88 % accuracy among patients. Frankie was trained to lie down in front of patients’ urine 
samples if he detected metastatic cancer.30  
Researchers have been focusing on developing biomimetic devices that capable of 
detecting cancer as seen in the dog, Frankie. Currently, the use of urine31 and breath32 as 
samples in cancer diagnosis has been employed due to their attractive noninvasiveness. 
When using urine samples as biofluids for analysis, one challenge is that the 
concentrations of naturally occurring biomarkers are typically low. To compensate for 
this limitation, an array of sensors with the ability to amplify biomarker concentration in 
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urine has been developed.33 For this purpose, a class of engineered mass-encoded 
peptides with specific protease-sensitive moieties conjugated to iron oxide NPs were 
synthesized. These synthetic biomarkers passively accumulate in the cancer tissue after 
administration. Aberrantly active proteases in the tumor subsequently cleave the 
protease-sensitive agents of these NPs, with the resulting fragments excreted in the 
urine.34 Using a library of different substrates as the protease-specific mass signatures, 
differentiation between different proteases was possible. The unique profiles of the 
isobar-coded reporters for each protease were identified. 
Another noninvasive sample type for PoC testing in cancer diagnosis is breath 
obtained from patients. Perhaps, breath sensing is the least invasive of all diagnostic 
strategies. Metabolic reactions in the body generate different volatile organic compounds 
(VOCs). These VOCs include hydrocarbons, alcohols, aldehydes, ketones, esters, nitriles 
and aromatic compounds. VOCs can be detected in diverse biosamples, such as cancer 
cells, blood, urine, skin/sweat35,36 and breath. In fact, besides cancer detection, VOCs are 
being used as new diagnostic-based biomarkers for detection of different diseases such as 
diabetes,37 Alzheimer’s, Parkinson’s,38 and chronic kidney disease.39 Compared with 
healthy individuals, cancer patients express different VOC compositions in their breath 
due to the different activities of cancer cells.32 These activities can generate very subtle 
changes in the concentration and composition of VOCs in the blood stream. Through 
constant exchange between the lung and bloodstream, these subtle changes in VOC 
compositions can be transported to the patient’s breath, creating distinct breath signatures 
for each cancer type.40 In a healthy breath, the concentrations of several VOCs are 
normally in the range of 1–20 p.p.b.12 However, they can be detected in the levels of 10–
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100 p.p.b. in some cancer types. These changes in concentration and composition mixture 
of VOCs have made it possible to not only distinguish between the breath of healthy 
individuals and cancerous patients, but also differentiate between different types of 
cancer.12,32 Previously, VOCs have been detected using gas sensors such as gas 
chromatography,41 and ion mobility spectrometry.42 However, the downsides to these 
methods are that they are time consuming and require large size, expensive 
instrumentation and an expert operator. Moreover, to improve the detection in some of 
these devices, capturing and preconcentrating the breath sample is a prerequisite step.43,44 
Using the advantages of NPs, a nanoscale artificial nose has been designed by Haick and 
co-workers.44 This simple, cost effective and portable sensor is able to detect cancer by 
analyzing the VOCs using pattern recognition methods. The nanoscale artificial nose is 
capable of identifying different odors even at very low concentrations and subtle 
differences.44 The gas sensor is based on an array of highly cross-reactive chemiresistors 
made of AuNPs with different organic capping layers. In the resulting sensor, electrical 
conductivity was provided by the metallic particles and the organic capping layers create 
sites used to capture the analytes.12  
Due to the chemical diversity of sensor materials, each sensor of the array shows 
a unique response to a certain group of VOCs. This means that the characteristic signal 
(electrical resistance) of each sensor in the array changes specifically when exposed to a 
specific VOC, which could be the cancer specific odor.44 Consequently, for each cancer 
type, a distinct fingerprint is produced from the array of cross-reactive sensors. Using this 
gas sensor along with pattern recognition methods, it is possible to discriminate different 
cancer types and stages.32,45 It is also worth mentioning that these sensor arrays have 
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detection limits of 1–5 p.p.b. or even down to approximately 10 p.p.t.32 Breast, lung, 
colon, gastric, colorectal, head-and-neck and prostate cancer are the cancer types that 
have been detected using this sensor. Carbon nanotube arrays have been used in a similar 
fashion.46,47 
It should also be mentioned that although breath sensing is a novel method for 
cancer detection, the approach has some limitations. First of all, there are not dramatic 
changes in VOCs in the early stages of cancer development; only certain stages will 
cause the expression of these VOCs. Second, the conditions and type of foods and drinks 
consumed by patients can influence results. The results can also be affected if the patients 
have other diseases and are using other medicines.32 Therefore, having sufficient controls 
over sample collection is essential when using this type of noninvasive sample. 
 
1.6. Chemometric analysis for data processing 
 
In an array-based sensing strategy, each analyte produces a response from each of 
the sensor elements. A multivariate data matrix is obtained from different analytes. As a 
result, a large number of generated data has to be analyzed quickly and efficiently to 
establish high quantity of fingerprints for identification. These data can be analyzed using 
multivariate chemometrics methods. These methods consist of a collection of techniques 
that can be used when several measurements are done on each individual analyte. Among 
these techniques, principal component analysis (PCA) and linear discriminant analysis 
(LDA) are most commonly used. These methods reduce the dimensionality of the data 
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sets by extracting the most useful information into new and simpler components called 
principal components or canonical factors for LDA.  
PCA is one of several multivariate methods that explore patterns in these data. 
PCA can determine the general relationship between these data by indicating which 
analytes behave similarly (in another words, which analytes belong to a similar group). 
While it is useful to know the pattern of these data, identifying which group a new 
unknown analyte belongs to is necessary. LDA as a classification (supervised pattern 
recognition) method is used for this purpose. In the classification methods, samples with 
known identities are used to define the groups (classes). These known sets of samples are 
referred to as a training set. The unknown analytes can then be assigned to the predefined 
groups using the appropriate classification algorithm.48,49 In the present dissertation, we 
extensively utilized LDA for data analysis using SYSTAT software (version 11). 
 
1.7. Dissertation overview   
 
 Chemical-nose sensing approach has proved to be an effective strategy for 
profiling biorelevant targets such as proteins, glycans, and mammalian cells. However, it 
is still a long haul to implement chemical-nose sensors in clinical applications due to 
certain challenges discussed in section 1.2. Addressing the challenges associated with 
chemical-nose approach is critical to close the gap from basic research to practical 
applications. Keeping this goal in mind, my research has focused on fabricating 
biocompatible sensor elements for healthcare applications using supramolecular 
chemistry of functionalized AuNPs, fluorescent proteins, fluorescent polymers and 
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enzymes. This dissertation covers three main themes: cancer therapeutic drug profiling 
and cancer diagnostics (Chapter 2-4), environmental toxicity (Chapter 5), and bacterial 
detection (Chapter 6) (Figure 1.5).  
 
Figure 1.5. Overview of the dissertation, which includes the use of nanoparticle-proteins, 
fluorescent polymers, and nanoparticle-enzyme for healthcare applications. 
 
In the first theme where cancer is the topic of interest, Chapter 2 discusses the 
use of supramolecular complexes between cationic AuNPs and three fluorescent proteins 
(FPs) for mechanism profiling of chemotherapeutic drugs in a high-content screening 
manner. Chapter 3 focuses on the improvement of chemical-nose sensors for cancer 
diagnostics based on the 3-channel platform established in Chapter 2. In this chapter, an 
innovative supramolecular interaction was used to double the output channels of a sensor 
array without additional synthesis. This simple approach provides single-well 
identification of cancer cell lysates and opens up a new dimension for array-based sensor 
design. The system also uses minimal sample quantity of cell lysates (200 ng, ~1000 
cells), making the methodology compatible with microbiopsy technology, a step closer to 
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PoC testing. Chapter 4 presents the transformation of chemical-nose sensor in the PoC 
testing field. This chapter discusses the use of a polymer-based sensor to rapidly detect 
cancer, based on changes in serum protein levels. Using this approach, only small 
quantity of serum sample is needed, allowing a rapid and simple test for cancer 
diagnostics. The system was validated using serum collected from different animal 
models. This polymer-based sensor holds the potential to stand at the forefront of the 
field as it solves the problem of multiple array components typically found in chemical-
nose sensors, along with the ease of detection using serum. In this system, only two 
polymers were used while maintaining high sensitivity and specificity for cancer 
detection, exceeding the standard clinical benchmark.  
In the second theme of environmental health, Chapter 5 discusses the extended 
use of nanoparticle and green fluorescent protein complexes in a cell-based assay to 
detect cellular changes due to hormone disruptor exposures. The use of our sensor in this 
application offers a simple way of screening toxic chemicals released into the 
environment.  
In the third theme of bacterial detection, Chapter 6 discusses the need of a PoC 
test for bacteria that can be used in the field. The supramolecular complexes between 
nanoparticles and enzymes provide a highly efficient sensor platform for bacteria using 
human sense of smell as an output, a convenient way that promotes equipment-free 
sensing platform. 
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CHAPTER 2 
 
A MULTICHANNEL NANOSENSOR FOR INSTANTANEOUS READOUT OF 
CANCER DRUG MECHANISMS 
 
2.1. Abstract 
 
Screening methods that use traditional genomic,1-3 transcriptional,4 proteomic,5,6 
and metabonomic7 signatures to characterize drug mechanisms exist. However, they are 
time-consuming and require specialized equipment. Here, we present a high-throughput 
multi-channel sensor platform that can profile the mechanisms of various 
chemotherapeutic drugs in minutes. The sensor consists of a gold nanoparticle (AuNP) 
complexed with three different fluorescent proteins (FPs) that can sense drug-induced 
physicochemical changes on cell surfaces.8-10 In the presence of cells, FPs are rapidly 
displaced from the AuNP surface and fluorescence restored. Fluorescence "turn on" of 
the FPs depends on the drug-induced cell surface changes, generating patterns that 
identify specific mechanisms of cell death induced by drugs. The nanosensor is 
generalisable to different cell types and does not require processing steps prior to 
analysis, offering an effective way to expedite research in drug discovery, toxicology and 
cell-based sensing. 
 
2.2. Introduction 
 
Rapid determination of the mechanism of drug candidates would greatly facilitate 
the discovery and optimisation of new therapeutics,11 particularly in the emerging area of 
personalised medicine.12 Recently, “signature”-based profiling of drug mechanisms has 
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provided a powerful strategy in drug discovery.1,2,13-16 These screening methods measure 
a series of molecular/phenotypic changes of cells/multicellular organisms induced by 
chemotherapeutic agents and create a fingerprint that is used as a reference for 
uncharacterized compounds. Several signature-based drug screening studies using 
traditional intracellular biomarkers1-7 require multi-step processing of cells such as 
extracting biomarker1,2,4,5 or labeling cells6,14 and specialized equipment, limiting 
adoption of these strategies in rapid drug screening.  
Cell surface phenotypes have been utilized in sensing cell states using 
nanoparticle-based array sensors.17,18 These sensors follow a hypothesis-free signature-
based strategy14,16,19-22 that allows them to be “trained” to identify diverse bioanalytes.  
However, the single channel output of these nanosensors required separate measurements 
for each array element, and were unable to differentiate between subtle cell surface 
phenotypic differences arising from different cell death mechanisms. We introduce a new 
multiplexed three-channel sensor platform created through supramolecular 
assembly/disassembly of a functionalised AuNP with three FPs. The simultaneous triple-
channel fluorescence transduction provides a ratiometric output that enhances the 
accuracy of measurements. Moreover, the information-rich output allows determination 
of chemotherapeutic mechanism from a single measurement that provides answers far 
faster (minutes) than current methods, and using standard laboratory instrumentation. 
 
 25 
	  
Figure 2.1. Assembly and working principle of the nanosensor. (a) Fabrication of the 
three-channel nanosensor (BenzNP–FPs complex). The sensor was prepared by 
incubating BenzNP to an equimolar mixture of three FPs at a ratio that was determined 
through fluorescence titration. (b) Schematic diagram illustrating the displacement and 
fluorescence turn-on of FPs by cell-surface functionalities. (c) Differential affinity of 
BenzNP to tdTomato (red), EBFP2 (blue) and EGFP (green) protein. The association 
constant (Ka) was determined through titration of equimolar mixture of FPs with BenzNP. 
 
2.3. Results and Discussion 
 
The sensor was generated by non-covalent conjugation of a benzyl headgroup-
terminated AuNP (BenzNP, Fig. 2.1a) with three FPs (EBFP2, EGFP and tdTomato). The 
FPs serve dual roles of exhibiting differential supramolecular affinities with the particle, 
and transducing the binding events. BenzNPs were used in the sensor based on our 
previous studies that indicated its effectiveness in profiling cell surface phenotypes.17 In 
these BenzNP-FP supramolecular complexes, the cationic AuNP binds strongly with the 
anionic FPs, resulting in quenching of the FP fluorescence by the particle core. The 
binding equilibria between BenzNP and the FPs are altered in presence of cells due to 
competitive binding to cell surfaces, resulting in rapid (seconds/minutes) displacement of 
FPs from the particle surface with consequent restoration of FP fluorescence (Fig. 2.1b). 
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The fluorescence "turn-on" of the three emission channels differs considerably depending 
on the signatures of drug-treated cell surfaces.   
A key issue in the sensor design is selecting appropriate FPs from the broad range 
of variants23 such that they provide reproducible sensor responses. Through tests with 
different FP variants we selected a three color FP set for the present study: blue (EBFP2), 
green (EGFP), and red (tdTomato). This optimized set of proteins was selected to: (i) 
bear net negative charge and feature minimum spectral ‘crosstalk’ with well-separated 
excitation and emission spectra, obtaining independent responses from each channel, (ii) 
exist as monomers or tandem dimers, simplifying their use in displacement assays 
relative to other multimeric analogs, (iii) be photostable, providing reliable outputs.   
A second requirement for the FP transducer is differential and reversible 
interaction with BenzNP recognition element. We determined the binding parameters by 
fluorescence quenching studies that provided the complex stability constant and 
association stoichiometry for each FP. It was observed that the binding affinities of 
BenzNP and FPs varied over three orders of magnitude (Fig. 2.1c), providing the 
differential affinity required for multi-channel output.  
We demonstrated the ability of the BenzNP-FP sensor platform to categorize 
chemotherapeutic mechanisms using a set of apoptosis- and necrosis-inducing chemical 
agents with established mechanisms. These clinical and experimental drugs cover 
common mechanisms of therapeutic action in cancer and include several groups with a 
common target (macromolecule/pathway). The necrotic agents induce cell death by rapid 
plasma membrane rupture,24 which would be expected to generate a strong surface 
response. Apoptotic drugs cause programmed cell death that is associated with alterations 
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of the plasma membrane including translocation of molecules from the cytosol, as well as 
suppression of signaling macromolecules.8-9,10,24 We tested the hypothesis that these 
drug-induced cell surface alterations could be rapidly discerned using the nanosensor. We 
used BT549 human breast cancer cells (triple negative) as a testbed for profiling 
chemotherapeutic mechanisms, since chemotherapy serves as the only systemic therapy 
for patients with this type of cancer.25 
	  
Figure 2.2. The nanosensor-based drug screening workflow. The Schematic diagram 
illustrates the drug screening workflow. Cells cultured in a 96-well microplate are treated 
with chemotherapeutic drugs at their IC50 concentrations for 24 h followed by washing 
and incubation the nanosensor. Different drug-treated cells result in distinct cell surface 
phenotypes and hence different FP displacement patterns as schematically shown for the 
three wells. The bar plot shows differential fluorescence responses for three 
representative drugs that may corroborate with the schematic of FP displacement. The 
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change in fluorescence along three channels was recorded simultaneously, where I0 and I 
are the fluorescence intensity before and after the addition of the sensor to the cells, 
respectively. The responses are averages of eight replicate data and the error bars 
represent ±standard deviation. 
 
Drug screening studies followed the straightforward protocol shown in Fig. 2.2. 
Cell culture, drug treatment, and the sensing studies were carried out in a single well of a 
96-well microplate. For consistency, the cells were treated with drugs at their half-
maximal inhibitory concentrations (IC50). We confirmed that the number of cells attached 
to the plate for each drug was consistent, ensuring that sensor differentiation arose from 
difference in cell surfaces. Notably, the sensor itself did not exhibit any cytotoxicity and 
cellular uptake of the particle is negligible within the short experimental time,26 making 
our sensing strategy non-interfering in terms of cell behavior. 
Initially, we used 15 chemotherapeutics that act through different molecular 
mechanisms (Fig. 2.3a) to generate a reference set based on fluorescence responses. 
Upon interaction with the drug-treated cells, the sensor generated characteristic 
fluorescence fingerprints for the three FPs. The distinct responses along each FP channel 
arise from the differential non-covalent interactions such as electrostatic and π–π stacking 
with the different biomolecules expressed on the drug-treated cell surfaces. Hierarchical 
clustering analysis (HCA) of the fluorescence responses produced seven distinct clusters 
(Fig. 2.3a), each corresponding to an individual molecular mechanism. The differential 
response pattern in the heat plot demonstrates the sensitivity of the sensor to drug-
induced cell surface changes.  
 29 
	  
Figure 2.3. Screening of chemotherapeutic drug mechanisms using fluorescence 
fingerprints. (a) Heat map of the fluorescence response patterns for the reference drug set. 
Hierarchical clustering was performed on the log-transformed average of the fluorescence 
responses using a correlation metric and average linkage. The resulting dendrograms 
show the degree of association of the drugs, as well as each FP. Literature-reported 
mechanisms of each drug are listed next to the heat map. (b) Clustering the reference 
drugs via LDA of the fluorescence responses. The canonical scores were obtained from 
LDA on the fluorescence responses, and were plotted with 95% confidence ellipses 
around the centroid of each group. (c) Probabilistic predictions of drug mechanisms 
utlising the fluorescence signatures. The p-values were calculated for the averages of 
eight replicates using the shortest Mahalanobis distance to the centroid of the nearest 
cluster in the reference set that was derived from LDA. A p-value of <0.01 was 
considered to be evidence of a “novel” drug mechanism. 
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The multidimensional sensor data was quantitatively interpreted using linear 
discriminant analysis (LDA). LDA classified the 15 drugs into seven distinct clusters 
according to the different pathways/targets of the drugs (Fig. 2.3b). Notably, drugs with 
similar molecular mechanisms showed overlapping clusters that were quantifiably 
distinguishable from other mechanistic categories. The distinctly separate region between 
the apoptotic and necrotic groups demonstrates the ability of the sensor to demarcate 
between broader classes of cell death mechanisms. It should be noted that the group size 
may determine the broadness of each drug category, with some categories amenable to 
further subdivisions.27 We validated the robustness of the LDA method by leave-one-out 
cross-validation using a Jackknifed analysis. The between-group (mechanism) cross-
validation accuracy was 99%, indicating the trained classifier to be a reliable and robust 
statistical tool. The generality of our strategy was assessed using another cell line with 
entirely different genotype/phenotype, for example, pTD cells (murine mammary cancer 
cells) that provide an important testbed for exploring therapeutics to regulate oncogenic 
epithelial-mesenchymal transition.28 Characteristic fluorescence responses from the drug-
treated pTD cells were generated and yielded distinct mechanism-based clusters. These 
clusters were somewhat different than that observed with BT549, as expected based on 
the geno/phenotypic difference between cell lines (Figure 2.4). 
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Figure 2. 4. Drug screening using pTD cells. (a) Heat map of the fluorescence responses 
pTD cells when treated with 11 reference drugs, where I0 and I are respectively the 
fluorescence before and after the addition of the sensor to the cells. Agglomerative 
hierarchical analysis was performed on the averages of the fluorescence responses. The 
dendrogram shows degree of association. (b) Linear discriminant analysis of the 
fluorescence responses resulted in canonical scores with three discriminants explaining 
90.6, 8.5, and 0.9% of total variance and plotted with 95% confidence ellipses around the 
centroid of each group (based on the standard error of the mean). 
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Figure 2.5. Classification of unknowns outside the initial reference set using BT549 
cells. Updated canonical score plot was derived from LDA of the fluorescence responses 
from a combination of the initial reference set and the compounds with ‘novel’ 
mechanisms, and were plotted with 95% confidence ellipses around the centroid of each 
group (based on the standard error of the mean). The clusters corresponding to the 
‘novel’ compounds are coloured, while the initial reference set compounds are presented 
in black. 
 
The ability to identify the mechanism of lead compounds as either known or 
novel is a key issue in drug screening. In blinded experiments we assessed seven 
anticancer agents that exhibit mechanisms similar to the training set. We predicted the 
mechanism of the test compounds by determining the probability of a compound 
belonging to the closest reference group using an appropriate F-distribution for the 
minimum Mahalanobis distance obtained from LDA. Using a cutoff p-value of 0.01, the 
analysis correctly predicted the molecular mechanisms of the seven test compounds 
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(Figure 2.3c), demonstrating the capability of the sensor to screen 'real' unknowns. We 
next sought to examine if the sensor can identify compounds involving targets/pathways 
different from the reference set. Seven compounds with “novel” (i.e. outside the 
reference set) cell death mechanisms were tested using the nanosensor. Implementing the 
same probabilistic analysis, p-value for each compound was found to be less than 0.01 
(Figure 2.3c), indicating that the compounds were far from all the training groups and 
could be readily classified as “novel”. Furthermore, a follow-up LDA solution space 
including the reference and novel compound set showed clearly distinct clusters, while 
the drugs with similar targets paired with each other correctly (Figure 2.5), indicating the 
ability to update the training set with ‘new’ mechanistic groups with sufficient resolution. 
We tested the robustness of prediction by studying eight parallel replicates of the blinded 
unknowns and the novel compounds that resulted in 87.5% (98 of 112 samples) correct 
prediction (Figure 2.6). The capability of the sensor to discriminate between learned and 
potentially new mechanisms demonstrates the ability of the system to avoid false 
positives of mechanism identification. The ability of the sensor to stratify molecularly 
targeted drugs such as the HDAC and CDK inhibitors suggests its applicability to broader 
class of modern targeted drugs (targeting EGFR, HER2, PDGFR, VEGF, proteasome, 
etc)29 that cause up/downregulation of the receptors on cell surfaces.  
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Figure 2. 6. Prediction of drug mechanisms on parallel replicates using the triple-channel 
sensor. Fluorescence responses from the EBFP2, EGFP, and tdTomato channels were 
utilised to perform the statistical analysis. The p-values were derived from F-distribution 
on the minimum Mahalanobis distance of each replicate to the centroid of reference 
groups calculated by LDA. Based on the p-values, each unknown case (parallel replicate) 
was assigned to a mechanistic group of the reference set or regarded as ‘novel’. The 
blinded unknowns exhibits cell death mechanisms similar to the reference set, while the 
‘novel’ unknowns involve mechanisms completely different from the reference set. 
 
Combination therapy provides a complementary strategy to new drug discovery, 
greatly enhancing the efficacy of chemotherapeutics, e.g. by overcoming the drug 
resistance of cancer cells.30 Drug combinations produce therapeutic activities 
(synergistic, additive, or antagonistic)31 at different ratios of the individual components. 
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Thus, a cell surface-based quick screening of the therapeutic activities with respect to 
individual drug mechanisms should lead to predicting the contribution of each drug in 
their therapeutic combination.32,33 
	  
Figure 2.7. Profiling the mechanisms of drug combinations. (a) Determination of 
therapeutic activities of pairwise drug combinations using fractional inhibitory 
concentration index (FICI). Correlation of the synergistic combinations of (b) apigenin-
cisplatin, (c) puromycin-cisplatin, and (d) puromycin-apigenin with the single-drug 
mechanistic categories. The canonical scores were calculated for the pairwise 
combinations with the mechanistic groups that contain the single-drug components 
forming the combinations. The LDA-derived scores from the fluorescence responses 
were plotted with 95% confidence ellipses around the centroid of each group. The 
mechanistic categories consist of several drugs with the same mechanism, Topo II 
inhibition: daunorubicin, etoposide, doxorubicin, and apigenin; DNA crosslinking: 
cisplatin, chlorambucil, and oxaliplatin; Protein synthesis inhibition: anisomycin, emetin, 
and puromycin. Each drug was used in eight replicates. 
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We demonstrated the ability of our sensor to determine mechanistic correlation 
between individual drugs and their combinations using three apoptotic drugs: apigenin 
(APG), puromycin (PUR), and cisplatin (CSP). We utilized fractional inhibitory 
concentration index34 to select the synergistic drug combinations. Interestingly, pairwise 
interactions of the drugs showed synergy or additivity depending on the ratios of the 
individual drugs (Fig. 2.7a). Comparison of the APG-CSP synergistic pairs with the 
single-drug components indicated that both the combinations exhibited a DNA 
crosslinking-like mechanism, consistent with previous observations35 of APG enhancing 
the cytotoxicity of CSP. The LDA scores quantified the similarity of the signatures of 
APG-CSP synergistic combinations to CSP with p>0.01 (Fig. 2.7b). Similarly, the 
signature of the PUR-CSP(1:3) combinations revealed its close proximity to protein 
synthesis inhibition-like mechanism (Fig. 2.7c), suggesting CSP potentiating the PUR-
induced cytotoxicity. However, PUR-CSP(1:1) and the PUR-APG synergistic 
combinations were classified quite far (p<0.01) from their single-drug components (Fig. 
2.7c,d), indicating a mechanistically distinct cell surface phenotypic change that provides 
a potentially new therapeutic strategy. These representative examples indicate that the 
sensor can provide an information-rich strategy for predicting the mechanisms of drug 
combinations. 
 
2.4. Conclusions  
 
In summary, we demonstrated the creation of a novel multichannel sensor based 
on non-covalent supramolecular complexes. This sensor uses an engineered nanoparticle 
and three different FPs to provide a three-channel sensor that can be “trained” to detect 
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subtle changes in cell surface properties. This biocompatible nanosensor can identify 
specific mechanisms induced by different chemotherapeutic agents, using a single well of 
a microplate, making this strategy applicable to massively high-throughput screening. 
The simplicity and effectiveness of the system underscores its potential to accelerate drug 
discovery, greatly facilitating the development of new therapeutics and drug “cocktails”. 
This sensor system also provides a potential way forward for toxicology, providing a 
viable method to classify the tens of thousands of commercial chemicals for which no 
data are available. 
 
2.5. Experimental section 
 
2.5.1. Fluorescence titrations. In the fluorescence quenching experiment, an 
equimolar solution of the three FPs (100 nM each) was titrated with various 
concentrations of BenzNP ranging from 0 to 300 nM. The excitation/emission/cut-off 
wavelengths were 380/450/435, 475/510/495, and 550/585/570 nm for EBFP2, EGFP 
and tdTomato, respectively. The change of fluorescence intensity at the respective 
emission maxima was recorded on a Molecular Devices SpectraMax M3 microplate 
reader at 25 °C. Decay of fluorescence intensity of each FP was observed with increasing 
NP concentration. Nonlinear least-squares curve fitting analysis was employed to 
estimate the binding constant (Ka) and association stoichiometry (n) using a 1:1 binding 
model (Figure 2.8).36,37  
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Figure 2.8. Titration of FPs with BenzNP. Fluorescence titration of an equimolar mixture 
of the three FPs by BenzNP. The emissions for each FP were measured independently at 
the corresponding emission wavelengths. The data points are averages of three replicates 
and the error bars represent the ±standard deviations. The black solid lines through the 
data points represent the best curve fitting using the model of single set of identical 
binding sites. 
 
 2.5.2. Sensor preparation. First, a FP solution was prepared by mixing the FPs at 
the final concentration of 100 nM (for each FP). The BenzNP-FP sensor was generated 
by incubating the FP solution with BenzNP (at the final concentration of 150 nM) for 30 
min in 5 mM sodium phosphate buffer (pH 7.4). The FP and BenzNP-FP solutions were 
maintained in the dark to minimise photobleaching of the FPs, if any. This conjugate was 
then added to the drug-treated cells for screening studies. 
2.5.3. Cell culture. BT549 cell line was purchased from ATCC (ATCC® HTB-
122™). pTD cell line38 was donated by Prof. D. Josph Jerry. BT549 cells were cultured in 
DMEM media supplemented with 10% FBS and 1% antibiotics. Cells were grown in a 
humidified atmosphere containing 5% CO2 at 37 °C. The TD cells were cultured in 
DMEM high glucose media supplemented with 10% FBS and 1% antibiotics. At ~80% 
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confluence, cells were trypsinised and plated in 96-well plates (Greiner black-and-clear 
bottom) and cultured for the next studies. 
2.5.4. IC50 of the drugs. The IC50 values of the drugs were determined by 
Alamar blue assay. Cells were seeded at 10,000 (BT549 cells) or 15,000 (pTD cells) per 
well in 96-well microplates (Greiner black-and-clear bottom). After 24 h, the cells were 
washed twice with phosphate buffered saline (PBS) and treated with drugs at different 
concentrations. The drug treatment was continued for 24 h for all the drugs except 
hydrogen peroxide and sodium nitroprusside for which 5 h treatment was effective. Drug 
treatment was done in cell culture media lacking antibiotics. After the drug treatments, 
cells were washed with PBS twice and the percentage cell viability was determined by 
using Alamar blue assay following the manufacturer’s protocol (Invitrogen). The IC50 
values were determined by fitting the data using a dose response model with variable Hill 
slope built in OriginPro 8.5 (Figure 2.9).  
	  
Figure 2.9. Determination of IC50 value of the single cytotoxic compounds. 
Representative dose response curves of (a), apigenin, and (b, puromycin using 10,000 
BT549 cells following 24 h drug treatment. The IC50 values were determined by fitting 
the data (the red line) using dose response model with variable Hill slope built in 
OriginPro 8.5. The data are averages of three replicates and the error bars represent the 
±standard deviation. 
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Dose response studies for combination of drugs were followed in a similar 
method of single drug. Three drugs (puromycin (PUR), cisplatin (CSP), and apigenin 
(APG)) were chosen arbitrarily to study the drug combinations (Fig. 4). To determine the 
IC50 values, two drugs of a combination were added to confluent cells one by one at 1:1, 
1:3, and 3:1 ratio with varying concentrations (Supplementary Table 2). The 
concentrations of drugs used were same for all the different combinations (PUR-CSP, 
PUR-APG, and APG-CSP). The IC50 values were determined by fitting the data using the 
same dose response model (Figure 2.10). 
	  
Figure 2.10. Determination of IC50 value of the combination of drugs. Representative 
dose response curves of the drug combinations (a), PUR-CSP(1:3), (b), PUR-CSP(1:1), 
and (c), PUR-CSP(3:1) using 10,000 BT549 cells after 24 h of drug treatment. The IC50 
values were determined by fitting the data (the red line) using dose response model with 
variable Hill slope built in Origin 8.5 program. The data are averages of three replicates 
and the error bars represent the ±standard deviation. 
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 2.5.5. Drug screening studies. The drugs were purchased from VWR 
International, Sigma-Aldrich, and Tocris Bioscience. First, 10,000 (for BT549 cells) or 
15,000 (for pTD cells) cells/well were seeded in 96-well Greiner black-and-clear bottom 
microplates and allowed to grow in their respective culture media at 37 °C and 5% CO2 
for 24 h. Then, cells were washed twice with PBS and treated with the drugs at their 
respective IC50 concentrations. The drug treatment was continued for 24 h for the 
individual drugs as well as their combinations (except for hydrogen peroxide and sodium 
nitroprusside, which were treated for 5 h). Cells were then washed three times with PBS 
and incubated with the sensor for 15 min before taking the reading. Then, 200 µL of the 
BenzNP-FP conjugate was loaded into 96-well plates containing drug treated cells to be 
analyzed. After 15 min of incubation with the sensor, fluorescence intensities were 
monitored for each FP using a plate reader (Molecular Device Spectramax M3) at 25 °C. 
Appropriate filters were used to collect emissions from each FP. The 
excitation/emission/cut-off wavelengths were 380/450/435, 475/510/495, and 
550/585/570 nm for EBFP2, EGFP and tdTomato, respectively. Fluorescence responses 
were log2-transformed before employing the statistical analyses. 
2.5.6. Determination of FICI. The fractional inhibitory concentration index 
(FICI) was calculated using the following equation based on Loewe additivity:39,40 
                                                                                                                  
 
where, [A]C and [B]C are the concentrations of drug A and B in the combination 
associated with a particular level of effect, e.g., IC50, and [A]E and [B]E are the 
concentrations of A and B when used singly to produce the same level of effect. FICI < 1 
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indicates synergism, while 1 ≤ FICI < 4 indicates additivity, and FICI ≥ 4 indicates 
antagonism. 
 2.5.7. Hierarchical clustering analysis. Hierarchical clustering analysis (HCA) 
is an unbiased clustering approach.  HCA of the average data set was performed using the 
hclust function of the stats package of R assuming a complete linkage method.41 hclust 
begins with each case serving as its own cluster; at each step in the clustering process, the 
two most similar cases or clusters are joined; the process iterates until all cases fall into a 
single cluster. HCA allows cases with mechanisms outside the reference set to be 
identified as novel, if they are dissimilar from the other cases in the set; in this case, they 
are linked to the other cases/clusters relatively high in the dendrogram.  
2.5.8. Linear discriminant analysis. The raw fluorescence response data matrix 
was processed by classical linear discriminant analysis (LDA) using SYSTAT software 
(version 11.0, SystatSoftware, Richmond, CA, USA). In LDA, all variables were used in 
the model (complete mode) and the tolerance was set as 0.001. The raw fluorescence 
response patterns were transformed to canonical patterns where the ratio of between-class 
variance to the within-class variance was maximized, where the classes were defined as 
the drug mechanisms in the reference set. This defines the LDA solution space. To 
identify the unknown (blinded) samples, we first re-ran LDA on the reference set using 
the lda function in the MASS package42 of R; these results replicated the SYSTAT 
analysis.  Predicted classifications for the blinded samples were then obtained using the 
predict.lda function that uses the fluorescence response patterns of each new case to 
compute the Mahalanobis distance of that case to the centroid of each mechanism cluster 
in the LDA solution space (Fig. 3b).  Blinded cases are predicted to belong to the closest 
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mechanism class, defined by the shortest Mahalanobis distance. Because some distance is 
always shortest, LDA is incapable of identifying blinded or completely unknown samples 
as having novel mechanisms. However, by considering the expected distribution of 
Mahalanobis distances under these conditions, cases can be identified as outliers if they 
fall far from the closest centroid (i.e., have an associated p-value < 0.01).  
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CHAPTER 3 
CANCER CELL DISCRIMINATION USING HOST-GUEST ‘DOUBLED’ 
ARRAYS 
 
3.1. Abstract 
 
 We report a nanosensor that uses cell lysates to rapidly profile the tumorigenicity 
of cancer cells. This sensing platform uses host-guest interactions between cucurbit[7]uril 
(CB[7]) and the cationic headgroup of a gold nanoparticle (AuNP) to non-covalently 
modify the binding of three fluorescent proteins of a multichannel sensor in situ. This 
approach doubles the number of output channels to six, providing single-well 
identification of cell lysates with 100 % accuracy. Significantly, this classification could 
be extended beyond the training set, determining the invasiveness of novel cell lines. The 
unique fingerprint of these cell lysates required minimal sample quantity (200 ng, ~1000 
cells), making the methodology compatible with microbiopsy technology. 
 
3.2. Introduction 
 
Rapid methods for geno- and phenotyping cells are crucial for cancer prognosis 
and the design of therapeutic strategies for precision medicine.1,2  Discrimination between 
healthy and cancerous cells, and then geno/phenotyping to determine whether the cancer 
is a slow-growing variant or a highly aggressive form are all important for optimal 
treatment.3,4  The cell proteome provides a significant resource for determining cell 
tumorigenicity.5,6  Traditionally, biomarker-based approaches employing proteomics 
techniques such as electrophoresis and mass spectrometry have been used to detect 
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changes in cell state.7-9   These methods, however, require prior knowledge of the tumor, 
and are often not sensitive to subtle changes in proteomic signatures. In contrast, array-
based ‘chemical nose’ sensing provides an alternative strategy uses selective receptors to 
generate multiple output channels that are used to create patterns (training sets), 
analogous to olfaction.10-12 These outputs are then used to build a global diagnostic 
pattern that can be used to rapidly identify individual small molecule13-15 and 
biomacromolecular analytes.16,17 More recently, array-based sensing has been used to 
profile complex biosystems,18-20 including the use of cell lysates to rapidly profile 
geno/phenotype of cells and tissues for cancer diagnosis.21  
The traditional application of array-based sensing protocols uses spatially 
separated sensor units each with their own recognition element to provide the multiple 
outputs required for pattern generation.22-26 Some studies report materials that have 
multiple optical properties that can be employed to give multiple channels within a single 
receptor;27-31 however, even in this format, each optical signal must still be measured 
separately. In recent research, an alternative strategy employing a single nanoparticle 
recognition element with three different transducers (red, green, and blue fluorescent 
proteins (FPs)) was used to generate multi-channel outputs.  This approach greatly 
simplifies the sensor system physically, facilitating ‘one-well’ discrimination of complex 
biosystems, including identification of bacterial biofilms,32 mammalian cells,33,34 and 
determination of drug mechanisms.35 A key challenge with this strategy, however, is 
generation of sufficient non-interfering channels (e.g. fluorescent emission wavelengths) 
for effective pattern generation. 
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Host-guest chemistry is a versatile tool for noncovalent modification of polymers 
and nanomaterials, altering the structure and concomitantly the behavior of these 
materials.36-39  This approach has been widely used in many applications, including 
imaging,40 therapeutic delivery,41 and sensing.42  We hypothesized that a host-guest 
strategy could be used to increase the information content of array-based sensing 
platforms, facilitating their use in cancer identification and typing. In our approach, we 
used noncovalent modification of a cationic benzylammonium-functionalized 
nanoparticle with a complementary cucurbit[7]uril (CB[7]) moiety (Figure 3.1).43,44  This 
binding modulates the interaction of the particle with both the fluorescent protein 
transduction elements and the cell lysate analytes. This change in competitive binding 
effectively doubles the number of output channels from three to six while maintaining the 
one-well configuration. This increased information content allowed facile discrimination 
of cells by their tumorigenicity. Significantly, this classification could be extended 
beyond the training set, determining the invasiveness of novel cell lines. Full 
differentiation of cell types was achieved with as little as 200 ng of protein (~1000 cells), 
demonstrating the potential of this method for microbiopsy-based cancer diagnostics.45 
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Figure 3.1. Six channel-output in a single well. The fluorescence of FPs is quenched 
when the BenzNP-FP complexes are formed. Upon addition of cell lysates, three 
emission channels are obtained from the released FPs. In the same well, CB[7] is added 
to obtain three additional channels from the three FPs as a result of changed interactions 
between the analyte and newly formed complex, BenzNP-CB[7]. 
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3.3. Results and Discussion 
 
The sensor consists of two supramolecularly-related recognition receptors: 
BenzNP and BenzNP-CB[7]. BenzNP can bind to the CB[7] host molecule to rapidly 
form host-guest complexes.46 The binding events of BenzNP and BenzNP-CB[7] with the 
lysates are transduced by three fluorescent proteins: blue (EBFP2) (B), green (EGFP) 
(G), and red (tdTomato) (R). In the presence of BenzNP, the fluorescence intensity of 
FPs is quenched. Different amounts of FPs are then released after the addition of cell 
lysates due to their competitive binding for the particles, generating channels 1-3. Host-
guest interactions between CB[7] and BenzNP47  create the second recognition 
receptor.48,49  The addition of CB[7] triggered a drastic change in fluorescence intensity 
of the three FPs, indicating a stronger interaction of BenzNP-CB[7] complexes to FPs 
than the BenzNP,50-52 generating channel 4-6. CB[7] is a good synthetic receptor for 
peptides and proteins, which might contribute to the enhanced quenching ability of 
BenzNP–CB[7] toward FPs in the presence of lysates.53  To ensure that the fluorescence 
changes are induced by the interaction of BenzNP-CB[7] with cell lysates and not from 
any changes of  FPs themselves, we tested the effect of CB[7] and lysates on FPs alone 
and found that they do not affect fluorescence intensity of FPs (Figure 3.2). 
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Figure 3.2. Effects of (a) CB[7] and (b) cell lysates on three fluorescence proteins. Both 
CB[7] and 200 ng of cell lysates did not change the fluorescence intensities of the three 
fluorescence proteins significantly. Each value is an average of three replicates. 
 
The first step in our sensing was to determine the appropriate conditions for 
converting Benz-NP to BenzNP-CB[7]. The appropriate stoichiometry of CB[7] and 
BenzNP was determined by isothermal titration calorimetry (ITC) and the 100/1 ratio of 
CB[7]/BenzNP was used throughout our sensing experiments (Figure 3.3). We also 
measured the saturation point of CB[7]/BenzNP using fluorescence titration assay of 
BenzNP-FP complexes preincubated with 200 ng cell lysates and varied concentrations 
of CB[7]. The same ratio of 100/1 of CB[7]/BenzNP was observed for this assay (Figure 
3.4).  
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Figure 3.3. Isothermal titration calorimetry (ITC) measurements of BenzNP with CB[7]. 
The saturation ratio of CB[7]/BenzNP was determined to be 100/1. 
	  
	  
Figure 3.4. Fluorescence titration of BnzNP-FPs with lysates with varying concentrations 
of CB[7]. The saturation ratio of CB[7]/BenzNP was determined to be 100/1. 
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As an initial test of our method, five human cancer cell lines with different 
tissue/organ origins were used: MCF-7 (breast), SKOV3 (ovarian), Raji (blood), NCI-
H1299 (lung), HEK239T (kidney) (Table 1). We used fluorescence spectroscopy to 
generate "fingerprints" for the cell lysates obtained from the cultured cell lines. In 
practice, cell lysates were added to the BenzNP−FPs complex, readings taken, then 
CB[7] was added to generate BenzNP−CB[7] in situ, with subsequent readout. These 
fluorescence outputs were analyzed by linear discriminant analysis (LDA). Cluster 
separation on an LDA plot was generated based on their standardized Mahalanobis 
distance: the greater the distance the lower the probability of misclassification. When 
only three channels are used, there is substantial overlap among different cell lines, 
especially NCI-H1299, SKOV3, MCF7, and Raji for the BenzNP-FPs channels (Figure 
3.5a), and overlaps between NCI-H1299 with HEK-239T, and SKOV3 with MCF-7 for 
the BenzNP-CB[7] channels (Figure 3.5b). However, when all 6 channels are combined, 
all five cell lines are well separated (Figure 3.5c). 
 
Table 3.1. Features of five cancerous human cell lines with different tissue origins. 
 
 
One critical step in chemical-nose sensing is to challenge its reproducibility. For 
this purpose, we revalidated our sensor by using an unknown set of all five cell lines (5 
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cell lines × 8 replicates = 40 unknown cases). We were able to predict the identities of the 
38 out of 40 unknown cases with 95 % correct unknown identification (% CUI) in a 
single-well configuration using 6-channel system. When there are only three channels, 
the % CUI drops drastically (Figure 3.5d). 
An important challenge in cancer therapy is determining whether tissue/cells are 
benign or cancerous; if they are cancerous, then whether or not it has the ability to 
metastasize to other organs. We chose three different human breast cell lines to test our 
host-guest doubled array sensor: MCF10A (normal), MCF-7 (cancerous), MDA-MB-231 
(metastatic) (Figure 3.6a). The three cell lines also show differential fluorescence patterns 
that are clustered separately by LDA when 6 channels are used (Figure 3.6b). Similar 
trend is observed in the % CUI of these three human breast cell lines where the six 
channel system gives much better unknown identification of 96 % (23 out of 24 samples) 
compared to the three channels (Figure 3.6c). 
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Figure 3.5. Five human cancerous cell lines were clustered using Linear Discriminant 
Analysis (LDA) with the fluorescence responses from a) only three channels: BenzNP-
FPs and b) BenzNP-CB[7], c) all six channels. d) Correct unknown identification 
percentage of three sensing systems. Unknown population is 40 samples for five cell 
lines. 
 
To further validate our sensor with a more stringent test, we employed isogenic 
cell lines derived from BALB/c mice. These cells can provide a testbed for our sensor by 
avoiding the issue of individual-to-individual geo/phenotypic variation since they share 
the same genetic background but have different histological stages, as characterized in 
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vivo. TM40A has undetectable tumorigenicity (0 %), TM9 generated tumors in 38 % of 
the cases, while MC7-L1 quickly developed tumors and became highly metastatic in 
100% of tested mice (100% tumor) (Table 3.2). These challenging isogenic cell lines are 
also differentiated using our six channel system (Figure 3.7a). However, when only three 
channels are used, there is always some level of overlap between the non-tumorigenic 
(TM40A) and the low-tumorigenic group (TM9), while the high tumorigenic cluster is 
highly separated from the others. This indicates biological similarity between the non-
tumorigenic and the low-tumorigenic samples. This same trend is also observed in the 
fluorescence heat map, analyzed by hierarchical clustering analysis (HCA) using six 
channels, where TM40A while is separated from TM9, they still share the same sub 
branch with each other and are much more different than the high-tumorigenic cell line 
MC7-L1 (Figure 3.7b). These results of 10 cell lines confirm the benefit of increasing the 
number of channels in chemical-nose sensing system, not just for the classification of 
each group but most importantly, the accuracy in unknown identification (Figure 3.7c).  
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Figure 3.6. Three human breast cell lines with (a) different cell status were clustered 
using Linear Discriminant Analysis (LDA) with the fluorescence responses from (b) six 
channels. (c) Correct unknown identification percentage of three sensing systems. 
Unknown population is 24 samples for three cell lines. 
 
  
 
To further validate the versatility of our 6-channel system, we cultured two 
additional cell lines that have similar histological outcomes with the cell lines in our 
reference set but different identities. These cell lines are FSK7 (low-tumorigenic) and 
Table 3.2. Features of five breast cell lines. 
 
# Cell line Tissue origin Cell status 
Reference 
cell lines 
 
1 TM40A Breast Normal 
2 TM9 Breast Low-tumorigenic 
3 MC7-L1 Breast High-tumorigenic 
Cell lines outside 
of reference 
4 FSK7 Breast Low-tumorigenic 
5       MC4-L2 Breast High-tumorigenic 
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MC4-L2 (high-tumorigenic).54,55 The fingerprints of these two cell lines were compared 
to the reference set to predict their histological outcomes. LDA plots show the overlap of 
each unknown cell line with their corresponding tumorigenicity with 100 % accuracy 
(Figure 4, Table S6). This result strengthens the sensor reliability in identifying clinically 
relevant features of cells. Notably, translating results from one cell line to use as 
reference for other novel cell lines has not been achieved previously with chemical-nose 
sensors.  
 
	  
Figure 3.7. Three isogenic breast cell lines derived from BALB/c mice were clustered 
using Linear Discriminant Analysis (LDA) with the fluorescence responses from a) six 
channels. b) Heat map of the fluorescence response patterns for the reference set using 
six channels. Hierarchical clustering was performed on the normalized average of the 
fluorescence responses, where I0 is the initial fluorescence intensity of the sensor and I is 
the final fluorescence intensity of the sensor after lysate incubation. c) Correct unknown 
identification percentage of three sensing systems. Unknown population is 24 samples for 
three cell lines. 
 
 
 60 
	  
Figure 3.8. (a) Unknown cell lines were clustered with the established reference cell 
lines via LDA by using the fluorescence responses from all six channels. (b) The correct 
unknown identification percentage of FSK7 and MC4-L2 are both 100 %. 
 
3.4. Conclusions  
 
In summary, we have used host-guest chemistry to double the information content 
of an array-based sensor for cancer diagnostics. The sensor was able to readily 
discriminate phenotypic changes among cells based on their complex proteomic 
signatures associated with different histological outcomes. The unique fingerprint of 
complex cell lysates can be obtained in a single well with minimal sample quantity (200 
ng of total proteins), minimizing biopsy size, reducing the invasiveness of the 
methodology. Significantly, the classification of this host-guest-based sensor could be 
extended beyond the training set, determining the invasiveness of unknown cell lines that 
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have similar histological outcomes. In a broader context, this host-guest-based chemical 
nose sensor presents a general means of increasing dimensionality in array-based sensors. 
 
3.5. Experimental section 
 
3.5.1. Cell culture. Raji cell line was donated by Professor Rachel M. Gerstein 
(Department of Microbiology and Physiological Systems, University of Massachusetts 
Medical School). MCF10A, TM40A, TM9, MC7-L1, FSK7, and MC4-L2 cell lines were 
donated by Professor Joseph Jerry (Department of Veterinary and Animal Science, 
University of Massachusetts Amherst). Raji was cultured in RPMI-1640 media 
supplemented with 1% glutamine, 1% non essential amino acid, 1% Sodium Pyruvate, 50 
µM β-mercaptoethanol, 10% FBS, and 1% antibiotic solution. MCF10A was cultured in 
DMEM/F-12 media supplemented with 5% horse serum, 1% penicillin/streptomycin,10 
µg/ml insulin, 20 ng/ml EGF, 0.5 µg/ml hydrocortisone, and 100 ng/ml cholera toxin. 
TM40A, TM9, MC7-L1, FSK7, MC4-L2 were cultured in DMEM:Ham’s F12 (1:1) 
media supplemented with 2% ABS, 25 mM HEPES, 10µg/ml insulin, 5 ng/ml EGF, and 
1% antibiotics. MCF-7, SKOV3, HEK239T were cultured in DMEM media 
supplemented with 10% FBS and 1% antibiotics. MDA-MB-231 was cultured in 
DMEM/High Glucose media supplemented with 10% FBS and 1% antibiotics.  NCI-
H1299 was cultured in RPMI-1640 media supplemented with 10% FBS and 1% 
antibiotic solution. All cells were grown in a humidified atmosphere containing 5% CO2 
at 37 °C. 
3.5.2. Cell lysate preparation. At about 80% confluence, cells were washed with 
ice cold PBS to remove all the loosely bound serum proteins in the media before adding 
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1mL of protease inhibitor-contained lysis buffer (0.15 mmol/L NaCl, 5 mmol/L EDTA, 
1% Triton-X 100, 10 mmol/L Tris-HCl (pH 7.4), plus half a tablet of complete protease 
inhibitor cocktail in 50 mL of buffer (Roche Diagnostics GmbH)). These cell flasks were 
stored at 4 oC for 15 minutes to ensure the lysis of the cell membrane. After 15 minutes, 
the cells were scraped with a sterile scraper, transferred to an eppendorf tube to be 
centrifuged down at 4 oC for 20 minutes at 14,000 rpm. The supernatant which contains 
cellular proteins were then quantified using BCA assay. For cell lysate sensing 
experiment, 200 ng of total protein from each cell line was used.  
3.5.3. Fluorescence titrations. In the fluorescence quenching experiment with 
BenzNP, an equimolar solution of the three FPs (100 nM each) was titrated with various 
concentrations of BenzNP ranging from 0 to 300 nM. The excitation/emission/cut-off 
wavelengths were 380/450/435, 475/510/495, and 550/585/570 nm for EBFP2, EGFP 
and tdTomato, respectively. The change of fluorescence intensity at the respective 
emission maxima was recorded on a Molecular Devices SpectraMax M3 microplate 
reader at 25 °C. For the CB[7] titration with BenzNP-FPs complex, the optimized 
concentration of the sensor complex (150 nM BenzNP and 100 nM each FPs) was first 
mixed together and 200 µL of this mixture was added into the 96 well plate. To test the 
releasing capability of FPs, 200 ng of Lipase (prepared in the same lysis buffer as other 
cell lysates) was added into BenzNP-FPs mixture and this mixture was incubated for 15 
minutes. Then, 10µL of a series of CB[7] concentrations was added into the previous 
mixture to determine the ratio of CB[7] and BenzNP that can quench FPs. Nonlinear 
least-squares curve fitting analysis was employed to estimate the binding constant (Ka) 
and association stoichiometry (n) using a 1:1 binding model. 
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3.5.4. Sensing studies. BenzNP-FPs conjugates were generated by mixing 150 
nM of BenzNP and each FPs (100 nM) in 5 mM sodium phosphate buffer (pH 7.4). Then, 
200 µL of BenzNP-FPs complex solution was loaded into a 96-well microplate, and 
initial fluorescence intensities (I0) of the quenched complexes were measured at 
450/510/585 nm. Then, 200 ng of each cell lysates was incubated with these complexes 
to determine the changes in fluorescence of the BenzNP-FPs complexes and establish the 
first three channels. After that, 10 µL of CB[7] was added into the 96 well plate using a 
Molecular Devices SpectraMax M3 microplate reader (at 25 oC).  
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CHAPTER 4 
SIMPLE AND ROBUST POLYMER-BASED SENSOR FOR RAPID CANCER 
DETECTION USING SERUM 
 
4.1. Abstract 
 
 We report a polymer-based sensor that rapidly detects cancer, based on changes in 
serum protein levels. This sensing platform utilizes the fluorescence signals from two 
charge-complementary polymers, and their fluorescence resonance energy transfer 
(FRET) to provide three ratiometric outputs. This simple system rapidly identifies cancer-
bearing mice in transgenic and xenograft mouse models. This sensor was validated by 
accurate prediction on blinded unknown samples, demonstrating the robustness of the 
approach. Taken together, this polymer-sensing platform provides an attractive strategy 
for point-of-care testing. 
 
4.2. Introduction 
 
Effective treatment of cancer requires early detection, making the creation of 
rapid and inexpensive sensing systems important for both health and healthcare cost 
reasons.1-3 Serum presents a minimally invasive target for the design of cancer 
diagnostics. A broad range of protein level in serum changes during tumor development.3-
5 Most techniques used for detection of cancer using serum focus on specific biomarkers. 
Enzyme-linked immunosorbent assay (ELISA) remains the method of choice.6,7 ELISA, 
however, has limitations in sensitivity for low-abundance biomarkers.  Most importantly, 
many cancer types do not have ideal biomarkers, due to widely different baseline 
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expressions of targeted biomarkers in the population, often leading to false positives and 
negatives in these tests.1b,8-10 Serum analysis can also be done by gel electrophoresis, 
coupled with mass spectrometry, but analysis time, quantification challenges, and 
expensive instrumentation are an issue.11-13 
‘Chemical noses/tongues’ provide an alternative to biomarker-based sensing and 
do not require previous knowledge of the analytes; instead they ‘train’ the sensor system 
to recognize analytes based on the overall subtle changes in complex mixtures.14-16 
Array-based sensors are composed of recognition and transduction elements, work hand 
in hand to establish a fingerprint for each analyte. An array of five gold nanoparticles 
detects proteins in human serum. Their binding was transduced by green fluorescent 
proteins (GFPs).17 Array-based sensors combine recognition and transduction, such as 
magnetic glyconanoparticle (MGNP) arrays18 and nanomaterial-assisted 
chemiluminescence.19 Overall, chemical noses and tongues are able to identify proteins,17 
carbohydrates,20 and mammalian cells21-23 in addition to white wines, fruit juices and 
non-steroidal antiinflammatories.24-26 
 Simplicity and scalability are important attributes for point of care (POC) 
diagnostics.27 To address this concern, we have directed our focus on a simple but robust 
polymer-based sensor system for profiling serum for cancer diagnostics. This system is 
based on the fluorescence signals of two charge-complementary conjugated fluorescent 
polymers and their fluorescence resonance energy transfer (FRET) to provide three 
ratiometric outputs. This polymer-only platform utilizes the structural diversity, 
fluorescence efficiency, stability, and scalability of conjugated polymer “molecular 
wires”28-32 to detect cancer in sera of cancer-bearing mice. The transgenic and xenograft 
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animal models used in this study plausibly recapitulate some of the clinically relevant 
events seen in individuals with cancer. 
	  
Figure 4.1. Schematic illustration of FRET-based polymer sensor for serum sensing. (a) 
Two polymers with opposite charges form supramolecular complexes through 
electrostatic interactions, generating FRET responses. The fluorescence intensities of two 
polymers and FRET responses are interfered with the addition of serum proteins. (b) 
Chemical structures and characteristics of polymers used in the study. Mn: number-
average molecular weight; Mw: weight-average molecular weight; PDI: polydispersity 
index. 
 
 
 
4.3. Results and Discussion 
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We designed two different backbones for our donor and acceptor polymers to 
provide an optimum FRET-based sensor, which is composed of polyfluorene sulfonate 
(PFS) and poly(p-phenyleneethynylen) (PPEs), respectively. Upon addition of serum, the 
fluorescence of each polymer, as well as their FRET process, are modulated due to the 
binding of serum proteins to the polymers. These fluorescence fingerprints are analyzed 
by linear discriminant analysis (LDA) to create a reference set (training set) and predict 
future unknown samples (Figure 4.1). Upon excitation at the PFS absorbance band of 365 
nm, the complexes PFS-PPE1 and PFS-PPE2 exhibit efficient FRET from PFS to PPEs. 
We observed the decreased fluorescence emission at 420 nm and sensitized emission at 
480 nm for PPE1 and 482 nm for PPE2 (Figure 4.2). 
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Figure 4.2. Emission spectra as a function of concentration of (a) PPE1 for the PFS-
PPE1 pair and (b) PPE2 for the PFS-PPE2 pair. Spectra were recorded at an excitation of 
356 nm for each pair in phosphate buffer saline (PBS), at pH 7.4. 
 
Table 4.1. Characteristics of eight proteins in PBS 
# Proteins Charge at pH 7.4 
Isoelectric 
point 
Molecular weight 
(kDa) 
1 Transferrin Neutral 6.1 80 
2 Fibrinogen - 5.5 340 
3 Human Serum Albumin - 5.2 69.4 
4 α1-antitrypsin - 4.6 52 
5 Myoglobin Neutral 7.2 17 
6 Lipase - 5.6 58 
7 Alkaline Phosphatase - 5.7 140 
8 Cytochrome C + 10.7 12.3 
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Figure 4.3. Fluorescence response from PFS-PPE1 sensor after eight protein incubation 
in PBS. 
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Figure 4.4. Comparison between two polymer pairs: PFS-PPE1 and PFS-PPE2. (a) Initial 
fluorescence spectrum (black) of the PFS-PPE1 complex and final spectrum upon 
incubation with pure calf serum (red). (b) LDA plot of the PFS-PPE1 complex responses 
to eight proteins in PBS at 10 µg/ml with a 100 % correct classification. HSA is Human 
Serum Albumin. The analysis resulted in canonical scores with two discriminants 
explaining 79.8 %, and 16.0 % of total variance and was plotted with 95% confidence 
ellipses around the centroid of each group. (c) Performance comparison between PFS-
PPE1 and PFS-PPE2 FRET pairs, where A is the classification accuracy of eight proteins 
detected in PBS, B is the correct unknown identification (CUI %) of these eight proteins 
in PBS, C is the classification accuracy of normal and cancerous mouse serum samples 
from the transgenic lung cancer model at different concentrations, and D is the CUI % of 
these mouse serum samples at different concentrations. (d) Limit of detection of PFS-
PPE1 complex in detecting normal and cancerous mouse serum samples from the 
transgenic cancer model at 1, 5, 10, and 20 mg/ml total protein concentrations, in the 
order from left to right. 
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After we determined the ratio of PFS and PPEs with a suitable FRET response, 
each pair was tested in calf serum, the addition of which caused a decrease in sensitized 
PPE fluorescence and an increase in the donor PFS fluorescence. This observation 
indicated dissociation of the complexes due to binding of serum proteins towards these 
polymers. These FRET-based sensors identify eight different proteins dissolved in 
phosphate buffer saline (PBS, pH 7.4) (Table 4.1). We observed distinct fluorescence 
changes for all eight proteins from each polymer pair, PFS-PPE1 and PFS-PPE2 (Figure 
4.3). LDA plots show correct classifications of different proteins (100 % and 97.0 %, 
respectively) but also successfully identified blinded unknown samples (98.4 % and 89.0 
%, respectively) (Figure 4.4b, c) and that in a matter of minutes. 
 
Table 4.2. Characteristics of tumor mouse models 
Model type Mouse strain 
Cell 
line 
Injection 
location 
Tumor 
induction 
time 
(days) 
# 
Control
s 
# 
Cancer-
bearing 
mice 
Transgenic 
lung cancer 
model 
129/Sv 
p53R172HΔg/
+ K-rasLA1/+ 
mice 
N/A N/A 100-300 5 5 
Experiment
al lung 
cancer 
model 
NIH-III 
(nu/nu; 
beige/beige
) mice 
H1299  Intracardia
c route 
55-120 5 5 
 
We validated the sensor using a more challenging test bed: cancer-bearing mice 
and healthy controls from a transgenic lung model (Table 4.2), established by mutations 
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in the Kras and p53 genes. We determined the total serum protein concentration 
necessary for the assay. Four different concentrations of normal and cancerous sera from 
the transgenic lung model were prepared and titrated with each sensor. The LDA plot 
shows separation of normal (upper) versus cancerous (lower) serum samples with a shift 
from left to right that associates with low to high concentrations of total proteins: 1, 5, 10, 
and 20 mg/ml (Figure 4.4d). Although sera from normal controls and cancer-bearing 
mice were differentiated at all four concentrations, we chose 5 mg/ml total serum proteins 
for further experiments because of its stable and differentiable fluorescence responses. 
Both sensors were able to classify all 8 clusters of 64 samples (4 concentrations × 2 
serum types (normal and cancerous) × 8 replicates). PFS-PPE1 performed better than 
PFS-PPE2 with 89.1 % versus 12.5 % (Figure 4.4c) in unknown identification and we 
chose the PFS-PPE1 pair for all of our mouse serum experiments. 
Serum protein levels vary from patient to patient even when they have the same 
type of cancer, one challenge for cancer diagnostics.33 This motivates us to examine the 
effect of individual differences from cancer-bearing mice of the same cancer model. We 
prepared five normal healthy controls (M1 to M5) and five transgenic cancerous mice 
(M6 to M10). The LDA plot shows distinct clusters for the control versus cancerous 
groups, with all five healthy controls and all five cancerous mice clustering together 
within their respective groups with 100 % accuracy (Figure 4.5a). To test the 
reproducibility of our PFS-PPE1 sensor, we generated 80 blinded cases (5 mice × 2 types 
(normal and cancerous) × 8 replicates) for unknown prediction (Figure 4.5b), results in 
98.7 % of correct unknown identification of normal and cancerous samples from the 
transgenic lung model (Figure 4.5c). 
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Figure 4.5. Detection of mouse serum samples from the transgenic lung cancer model 
using PFS-PPE1 complex. (a) LDA plot of the PFS-PPE1 complex responses to serum 
samples of five normal and five cancerous mice. The analysis resulted in canonical scores 
with two discriminants explaining 97.9 %, and 1.4 % of total variance and was plotted 
with 95% confidence ellipses around the centroid of each group. (b) Unknown mouse 
serum samples were clustered with the established reference serum via LDA using the 
fluorescence responses. (c) Results of unknown identification of 80 mouse serum samples 
using LDA algorithm. 
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Figure 4.6. Detection of mouse serum samples from lung cancer model using PFS-PPE1 
complex. (a) LDA plot of the PFS-PPE1 complex responses to serum samples of five 
normal and five cancerous mice. The analysis resulted in canonical scores with two 
discriminants explaining 95.8 %, and 3.6 % of total variance and was plotted with 95% 
confidence ellipses around the centroid of each group. (b) Unknown mouse serum 
samples were clustered with the established reference sera via LDA by using the 
fluorescence responses, resulted in a 100 % CUI. 
 
We tested the generality of the PFS-PPE1 sensor using another mouse model: a 
lung tumor model induced by H1299-EGFP-luc2 cells. This model includes 10 mice (5 
normal healthy mice and 5 cancerous mice) (Table 4.2). Similar to the transgenic cancer 
model, the LDA plot of this model differentiates between normal and cancerous mice 
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with 100 % classification accuracy (Figure 4.6).  Our assay also picks up the 
heterogeneity in different cancerous mice within the same tumor model. In all the mouse 
models, there are more variations among cancerous mouse samples than the normal 
controls. 
	  
Figure 4.7. Combined serum data from both models: transgenic and experimental lung 
models. (a) LDA plot of the PFS-PPE1 complex responses to combined cancerous serum 
samples and combined normal serum samples. The analysis resulted in canonical scores 
with two discriminants explaining 99.3 %, and 0.7 % of total variance and was plotted 
with 95% confidence ellipses around the centroid of each group. (b) Unknown mouse 
serum samples were clustered with the established reference sera via LDA by using the 
fluorescence responses, resulted in a 87 % CUI. 
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The ultimate goal of a diagnostic test is to answer the question of whether or not 
the patient has cancer. For this purpose, we combined all control samples from both 
transgenic lung and experimental lung models to serve as the reference for normal 
healthy mice, and cancerous samples from both models as the reference for cancer-
bearing mice. LDA analysis shows 91 % of classification accuracy between normal and 
cancerous samples from both cancer models. Unknown prediction for this combined-
model data set is also very effective, 87 % (Figure 4.7).  
 
	  
Figure 4.8. Receiver operating characteristic (ROC) analysis of the combined data from 
both transgenic lung and experimental lung models. The accuracy of the test depends on 
how well the test separates the group being tested into those with and without cancer. An 
ideal diagnostic test would have the true-positive rate equals one and the false-positive 
rate equals zero. AUC was calculated to be 0.95 with a sensitivity of 91.2 % and a 
specificity of 85.0 % using the cut-off level at 0.27. Cut-off level is the optimal threshold 
to maximize TPR while minimizing FPR. 
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An important and useful technique for evaluating the performance of diagnostic 
tests is the receiver operating characteristic (ROC) curve.34 Conventionally, the 
performance of a diagnostic test is usually summarized by two quantities related to the 
two types of errors: true-positive rate and false-positive rate. The true-positive rate is the 
probability that a patient with cancer is correctly classified as having cancer, and the 
false-positive rate is the probability that a patient without cancer is incorrectly classified 
as having cancer. In other word, the true-positive rate reflects sensitivity and one minus 
the false-positive rate reflects specificity. An ideal diagnostic test would have the true-
positive rate equals one and the false-positive rate equals zero. For cancer screening, the 
false-positive rate needs to be very low; otherwise, an inordinate number of screened 
healthy subjects will have unnecessary harmful therapies.35 Figure 4.8 shows the ROC 
analysis of the sensor when using the combined data from both transgenic lung and 
experimental lung models in the unknown identification. The AUC was calculated to be 
0.95 (95 % confidence level: 0.92-0.98) with a sensitivity of 91.2 % and a specificity of 
85.0 % using the cut-off level at 0.27. The AUC value obtained in our study is well 
within the excellent diagnostic accuracy range (AUC = 0.9-1.0).36 Our test is also well 
above the standard accuracy range required for most diagnostic tests37 and is more 
accurate compared to most tests using single specific biomarker.38-40 
 
4.4. Conclusions  
 
We demonstrated a robust FRET-based polymer assay, which rapidly 
differentiated healthy controls and cancer-bearing mice using their sera. In total, 224 
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cases from 20 mice were accurately and readily identified within only minutes. This 
sensor benefits from the highly responsive conjugated fluorescent polymers as well as the 
simplicity of minimal sensor elements (only two polymers). In addition, the stability and 
scalability of this polymer-based sensor make it an attractive strategy for point-of-care 
testing.27 More importantly, serum is an easy accessed biofluid, which allows a simple 
diagnostic and prognostic approach that poses low level of inconvenience to patients. 
 
4.5. Experimental section 
 
 4.5.1. FRET optimization. A series of concentrations of PPE1 and PPE2 were 
mixed independently with a constant concentration of the donor PFS at 0.2 µg/ml in 96 
well plate. All fluorescent spectra were recorded at room temperature using Molecular 
Devices Spectramax M5 plate reader with an excitation wavelength of 356 nm. PPE1 and 
PPE2 concentrations were varied between 0.04 to 2 µg/ml and 0.1 to 1.5 µg/ml, 
respectively. For the calf serum incubation study, each condition of each polymer pair 
was incubated with 10 µL of undiluted calf serum for 30 minutes. The optimized ratios of 
PPE1/PFS and PPE2/PFS were 1.5 and 5, respectively. To enhance the fluorescence 
intensity of PPE1 and PFS, we kept the same ratio for this pair but increased their 
concentrations to 0.75 and 0.5 µg/ml, respectively.    
4.5.2. Animal models. Mice were maintained on standard mouse chow, and 
housed in a specific pathogen-free barrier facility with ethics approval from the 
University of Calgary Animal Care Committee and in accordance with Canadian Council 
on Animal Care guidelines. Use of the non-small cell lung cancer model harboring 
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p53R172HΔg/+ and K-rasLA1/+ transgenes has been described earlier.41  Experimental 
Xenograft lung cancer model using H1299-EGFP-luc2 cells was previously described.42 
Following necropsy, organs were fixed in 10% formalin for an average of 24 to 48 hours. 
Skeletal tissue was then selected and placed into 88% formic acid for decalcification for 
an average of 4-6 hours. All tissue was then subject to routine processing (8 hour 
protocol) where tissue is sequentially placed into formalin then a series of graded 
alcohols (70% to 100%) followed by xylene and then paraffin wax infiltration. Tissues 
were then paraffin-embedded prior to sectioning and hematoxylin and eosin (H&E) 
staining. 
4.5.3. Mouse serum preparation. Blood was collected from hearts of mice using 
syringes and carefully transferred to 1.5 ml eppendorf tube. These blood-contained tubes 
were kept at room temperature for 45-60 minutes to induce blood clotting. After that, 
samples were centrifuged at 13,000 rpm for 15 min at 4° C. After centrifugation, 
supernatant was carefully aliquot into new eppendorf tubes for long-term storage at - 80° 
C. Sterile PBS (pH 7.4) was added to dilute each serum sample in the amount of 200 µL, 
in order to minimize serum lost after filtration. Each diluted serum sample was filtered 
using a sterile 4 mm diameter syringe filter purchased from Corning®, with 0.2µm pore 
RC membrane. The total serum protein concentration was determined by bicinchoninic 
acid assay (BCA) and normalized by diluting to the same concentration with PBS before 
sensing. 
4.5.4. Sensing studies. Appropriate concentration of each polymer was mixed 
together in PBS (pH 7.4) based on previous optimizations. Each of the PFS-PPE 
complexes was loaded (200 µL) into a black 96-well untreated plate (Costar), followed 
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by the addition of 10 µL of 210 µg/ml protein solution in PBS or 5 mg/ml total serum 
protein concentration of each mouse. The mixture was incubated for 30 minutes before 
their fluorescence intensities were recorded at EX/EM (nm) of 356/420, 408/480, 
356/480 for PFS-PPE1 pair, and 356/420, 418/482, 356/482 for PFS-PPE2 pair. The 
fluorescence intensities of the sensor only (without any analyte) is I0, while the intensities 
of the sensor with analytes after 30 minutes of incubation is I. Normalized fluorescence 
of each sample is I/I0.      
4.5.5. Receiver operating characteristic analysis (ROC). To evaluate how well 
LDA predicts the unknown samples, we ran ROC analysis. We used lda function in 
MASS package43 of R to train set 1 then use algorithm trained in set 1 to predict set 2. The 
ROC curve is created by plotting the true positive rate (TPR) against the false positive 
rate (FPR) at various threshold (cut-off level) settings using ROCR package. Cut-off level 
is the optimal threshold to maximize TPR while minimizing FPR to achieve the most 
effective diagnostic test. The accuracy of the test depends on how well the test separates 
the group being tested into those with and without cancer. Accuracy is measured by the 
area under the ROC curve, also known as AUC (the area under the curve). An area of 1 
represents a perfect test; an area of .5 represents a less accurate test. AUC was obtained 
by the auc function in pROC package. Sensitivity and specificity were weighted equally 
in the prediction. 
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CHAPTER 5 
RAPID DETECTION OF ENDOCRINE DISRUPTING CHEMICALS BY A 
NANOSENSOR AT ULTRA-SENSITIVE LEVEL 
 
5.1. Abstract 
 
 Endocrine disrupting chemicals (EDCs) interact with estrogen receptors (ERs), 
causing a range of adverse health effects. Current assays for EDC activity are slow and 
often lack sensitivity.  We report here an ultra-sensitive nanosensor that can detect 
estrogenic cellular changes in ER(+) MCF-7 cells rapidly (minutes) at levels orders of 
magnitude lower than generally used assays. Notably, the sensor responses at these ultra-
low EDC levels correlate with an increased synthesis phase (S-phase) cell population of 
EDC-treated cells. The nanosensor was also able to detect binary EDC mixture effects, 
with synergism observed for bisphenol A (BPA) - 17β-Estradiol (E2) and antagonism for 
Dicyclohexylphthalate (DCHP) - E2, and Benzo(a)pyrene (BaP) - E2. 
 
5.2. Introduction 
 
Endocrine disrupting chemicals (EDCs) are structurally diverse compounds that 
interfere with the endocrine system, cause a broad range of adverse effects.1-4 EDCs 
featuring estrogenic activity are of particular importance, posing a significant threat to 
reproduction and developmental processes in human and wildlife,5 In common with other 
toxicological threats, there are tens of thousands of chemicals in use whose estrogenic 
effects are unknown.  
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Proliferative assays that rely on increased cell reproduction upon exposure to 
EDCs are by far the most widely used test for estrogenic activity. The widely used E-
screen proliferative assay requires a six-day exposure period. The inability of this 
protocol to detect low-dose effects in the pico-and femtomolar range causes many false 
negatives.6-8 Recently, flow cytometry assay has been used to detect estrogenic responses 
arising from lower EDC concentration exposures by detecting the percentage of cells in 
the S-phase.6 This assay, however, requires substantial sample preparation and 
specialized instrumentation, limiting its ability to address the high throughput demands of 
environmental toxicology. Recently, engineered bacterial sensor was developed to screen 
estrogenic EDCs at low concentrations. However, while this technique is quite rapid and 
convenient, it does not measure the direct phenotypic changes after EDC exposures that 
are relevant at a cellular level. Therefore, this design is more susceptible to false 
positives.9  
The wide range of health issues generated by EDCs suggests that there is likewise 
a range of phenotypic consequences of EDC exposure at the cellular level. Predicting 
these changes on the molecular level is, however, quite challenging.10,11 To address this 
issue, we report here the use of a hypothesis-free nanosensor to detect estrogenic EDC 
response of cells at pico- and femtomolar levels. This sensor system uses a gold 
nanoparticle (AuNP) as a recognition element and green fluorescence protein (GFP) as a 
transducer.12 This sensor platform can capture the overall chemicophysical changes of the 
EDC-treated cells in minutes, avoiding false negatives due to the limitation of the typical 
single endpoint readout of current assays.13 The simplicity of this method makes it 
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likewise a practical tool for addressing the real-world challenge arising from mixtures of 
EDCs. 
 
5.3. Results and Discussion 
 
We used a sensor system composed of non-covalent complexes of AuNPs and 
GFPs. We chose the benzyl nanoparticle (BenzNP) due to its sensitivity to differences in 
cell surfaces.14  The fluorescence of the GFP is quenched when bound to BenzNP, with 
fluorescence restored upon displacement by cell surface functionality (Figure 5.1).15-17 
Human breast cancer MCF-7 cells were used in our study. This cell line is widely 
employed in EDC studies5,6,8 due to their high level sensitivity to estrogenic agents.18,19  
	  
Figure 5.1. Schematic illustration of the nanosensor. (a) The sensor consists of BenzNP 
and green fluorescence proteins (GFPs). The fluorescence of GFP is quenched when the 
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BenzNP–GFPs complexes are formed. (b) When nanosensor is added to cells with and 
without EDC treatment, due to the different phenotypes of untreated and treated cells, 
BenzNP interacts differently with the cell surface and releases different amount of GFP, 
generating signal output.  
 
     Our initial experiments focused on establishing the response of our sensor to   
E2 as a positive control. MCF-7 cells were plated in 96-well plate overnight before being 
treated with E2, using 10,000 cells/well. After 24-hour treatment, cells were washed with 
Phosphate Buffer Saline (PBS), followed by the addition of the nanosensor BenzNP-
GFP. The sensor detected significant cellular changes of E2-treated cells at femtomolar 
concentration (5 × 10-15 M). In contrast, there was no proliferative effect observed using 
Hoechst dye at even five orders of magnitude higher in E2 concentration.  Significantly, 
co-incubation of cells with E2 and the anti-estrogen ICI 182,780 generated a response 
identical to that of control (untreated) cells, verifying that the sensor was responding to 
estrogenic changes in cell phenotype (Figure 5.2a). Our nanosensor was able to detect 
cellular changes induced by femtomolar concentration of E2, a four order of magnitude 
more sensitive than the conventional E-screen assay.6,19 
 We next tested our system on bisphenol A (BPA), an EDC that has generated 
considerable controversy.20,21 The cells were treated with BPA for 24 hours prior to 
sensing. A significant increase in fluorescence signal from the sensor is observed at 
picomolar range (5 × 10-11 M, Figure 5.2b), while no significant response from Hoechst 
dye. Two other reported EDC agents, Dicyclohexylphthalate (DCHP), and 
Benzo(a)pyrene (BaP), likewise showed a positive response (Figure 5.2c).5,6,22 
Significantly, BaP was successfully detected by our nanosensor at the concentration of 1 
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× 10-11 M, even though no significant proliferative effect was observed with this EDC 
using a standard E-screen assay.6 
	  
Figure 5.2. Fluorescence response from nanosensor BenzNP-GFP and Hoechst 33342 
with and without co-incubation of estrogen receptor inhibitor ICI 182,780 with (a) 17β-
Estradiol (E2) and (b) Bisphenol A (BPA). Fluorescence response of BenzNP-GFP 
sensor is significantly increased in the absence of ER inhibitor ICI 182,780 in both E2 
and BPA treated cells at 10-15 M and 10-11 M respectively. (c) Fluorescence response from 
nanosensor BenzNP-GFP for all tested compounds: E2, BPA, Dicyclohexylphthalate 
(DCHP) and Benzo(a)pyrene (BaP). Each data point is the mean value of four replicates 
per treatment (n=4). 
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In reality, when we are being exposed to EDCs, it is usually a mixture of 
compounds and not a single agent. Therefore, it motivates us to investigate the low dose 
effect of EDC mixtures, starting with the binary mixtures of each tested compound 
described previously with a non-significant concentration of E2 at 1 fM. We used a sub-
threshold dosing of E2 with the purpose of making the effects of binary mixtures more 
apparent by eliminating the potential affect of E2 alone in higher concentrations. Series 
of BPA, DCHP and BaP concentrations were prepared with and without co-incubation of 
1 fM E2 to treat the cells for 24 hours before the detection by the nanosensor. To allow 
comparison across different compounds, equipotent concentrations (PC50) need to be 
calculated. PC50 indicates the concentration of compound x that evokes 50% activity of 
the positive control, E2. This approach is more suitable for comparison than EC50 due to 
the fact that not all compounds reach a relative proliferation effect of 100%.5,23 
Interestingly, BPA-E2 mixture shows a drastic increase in fluorescence signal compared 
to just single agent BPA. The PC50 of BPA-E2 mixture is much lower than that of BPA 
alone (4.77 × 10-14 M and 1.57 × 10-10 M, respectively). This reduction in PC50 makes the 
mixture of BPA-E2 even as potent as compared to E2 alone. This result is consistent with 
previously published work using the traditional E-screen method.24 Other tested binary 
mixtures of DCHP-E2 and BaP-E2 show an opposite trend with BPA-E2 mixture. While 
BPA-E2 mixture indicates a highly synergistic effect, DCHP-E2 and BaP-E2 show 
antagonistic effects, where their PC50 values could not be determined (Figure 5.3). The 
binary mixture of E2 and another phthalate derivative, butylbenzyl phthalate, was shown 
to be antagonistic in previous work.24 However, to the best of our knowledge, the mixture 
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behaviors of DCHP-E2 and BaP-E2 are not previously reported in the literatures and are 
new findings enabled by our technology.   
	  
Figure 5.3. Fluorescence response from nanosensor BenzNP-GFP for binary mixture 
effects of 1 fM 17β-Estradiol (E2) with (a) Bis-Phenol A, (b) Dicyclohexylphthalate, (c) 
Benzo(a)pyrene. Each data point is the mean value of four replicates per treatment (n=4). 
d) PC50 values for individual compounds and binary mixtures with 1 fM E2. PC50 value is 
the concentration of compound x with 50% activity of the positive control (17β-Estradiol, 
E2). 
 
Our sensor can rapidly detect cellular responses from ultra-low levels of 
estrogenic agents, raising the question of what phenotypic change was being detected. 
Estrogenic EDCs trigger cells to proliferate, which should result in an elevated 
population of S-phase cells. The S-phase cell population can be measured by flow 
cytometry. This method has been previously described as flow cytometric E-screen assay, 
and was validated using a range of estrogenic compounds.6 In our study, cells were 
treated with different concentrations of E2 and BPA for 24 hours, then trypsinized and 
washed with PBS. Ethanol was used to stabilize these cells at 4°C. After 2 hours, cells 
were stained with Propidium Iodine/RNAse solution before running flow cytometry. As 
 94 
observed in sensor response of E2 and BPA-treated cells, higher concentrations of E2 and 
BPA induced more S-phase cell population, which become significant at 2.5×10-14 M and 
1×10-11 M, respectively (Figure 5.4a). We observed a similar trend in the increased S-
phase population as seen with the nanosensor BenzNP-GFP response. This increase in S-
phase is eliminated when cells were treated with the co-incubation of E2 or BPA with the 
anti-estrogen ICI 182,780 (Figure 5.4b). The direct correlation between our sensing 
studies and the cytometric data provides solid evidence that our sensor is responsive to 
cell cycle changes. 
 	  
Figure 5.4. (a) E2 and BPA effects on S-phase cell population of MCF-7 measured by 
flow cytometry. The S-phase percentage of MCF-7 cells increases as the concentration of 
E2 or BPA increases. (b) Co-incubation effect of E2 and BPA with ICI 182,780, an 
estrogen receptor antagonist, on S-phase cell population. The proliferation effect of 
MCF-7 cells when treated with E2 or BPA is inhibited in the presence of 10 nM of ICI 
182,780. Each data point is the mean value of three replicates per treatment (n=3). 
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5.4. Conclusions  
 
We have demonstrated the usefulness of our simple nanosensor, BenzNP-GFP, 
for detecting low dose effects of estrogenic EDCs. This technique is rapid, versatile and 
only involves one step process of adding the nanosensor solution into the EDC-treated 
cells. We have successfully detected the estrogenic activity of an endogenous (E2) and 
other xenogenous agents (BPA, DCHP and BaP) on MCF-7 cells at ultra low 
concentrations (femto and picomolar ranges). The ease of performing this cell-based 
assay using BenzNP-GFP complex has made it possible to test the effects of EDCs at a 
broader range of concentrations. Whereas, a sensitive flow cytometry method still limits 
number of samples one can perform due to multistep processing procedure. Significantly, 
this nanosensor can also be used to detect EDC mixture effect, eliminating the lengthy 
processing time comes with infinite number of possible combinatorial EDC mixtures. 
Studying the combination behaviors is a step forward to better reflect the effects of EDCs 
in a more complex system, such as in vivo. Such complexity can be complicated by the 
pre-existence of endogenous estrogen, which when mixed with other xenogenous 
substances, might be drastically different compared to single agent itself as observed in 
our study. 
 
5.5. Experimental section 
 
5.5.1. Nanosensor (BenzNP and GFP) fabrication. To determine the 
appropriate ratio of BenzNP and GFP for the assay, different concentrations of BenzNP 
were first titrated with 150 nM GFP to find out at which concentration of BenzNP, GFP 
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intensity can be quenched. Final concentrations of 100 nM BenzNP and 150 nM GFP 
were used for all assays. The appropriate ratio of BenzNP and GFP was mixed with 5mM 
Phosphate buffer (5mM PB) for 30 minutes to form nanosensor complexes and quench 
the fluorescence intensity of GFP. This mixture was then added to cell microplate for 
estrogenic activity detection. 
5.5.2. Cell culture. For routine cell culture, MCF-7 cells were maintained in 
Dulbecco’s Minimum Essential Medium (DMEM) with phenol red as pH indicator, 
supplemented with 10% Fetal Bovine Serum and 1% antibiotics. Cells were grown in a 
humidified atmosphere containing 5% CO2 at 37 °C. For estrogenic activity experiments, 
MCF-7 cells were cultured in low steroid conditions with charcoal dextran treated fetal 
bovine serum (CDFBS) in order to minimize estrogenic activity of serum and arrest all 
cells at G0/G1 phase. More specifically, cells were transferred to DMEM-F12 (phenol red 
free due to its known estrogenic activity) media, supplemented with 5% CDFBS and 1% 
antibiotics for 3 days. After that, cells were seeded on 96-well plate for experiments using 
only 2.5% CDFBS DMEM-F12 media to avoid cell overgrown and enhance estrogenic 
effect in a serum deprived environment.  
5.5.3. Cell number titration. a series of cell number from 2,000 to 10,000 cells 
were plated on 96-well plate overnight (Figure 5.5). BenzNP-GFP complex solution with 
co-incubation of Hoechst 33342 was added to the 96-well plate after one time washing 
with Phosphate Buffer Saline (PBS). Alamar Blue/cell media solution was prepared in 
the ratio of 1/10. This mixture was incubated with cells for approximately 3 hours before 
being read out at EX560/EM590.   
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5.5.4. Cell-based assay for estrogenic activity detection. 10,000 cells were 
seeded on 96-well plate in 2.5% CDFBS DMEM-F12 media overnight. A series of E2 or 
BPA concentrations were prepared in 2.5% CBFBS DMEM-F12 media with 0.1% EtOH. 
Cells were washed with PBS and treated with these concentrations for 24 hours. After 
that, cells were washed one more time with PBS. Appropriate ratio of BenzNP-GFP 
nanosensor was mixed with 10 µg/ml of Hoechst 33342 and added into 96-well plate for 
15 minute incubation time. The GFP and Hoechst fluorescence were measured with 
EX/EM wavelengths of 475/495 nm and 355/460 nm on a Molecular Devices 
SpectraMax M3 microplate reader at 25 °C. Normalization of fluorescence intensity was 
done by I/I0, where I is the final fluorescence intensity and I0 is the initial fluorescence 
intensity of the sensor. 
5.5.6. Flow cytometry and cell cycle analysis. Serum deprived cells were seeded 
on 6-well plate at a density of 180,000cells/well in CDFBS DMEM-F12. Six 
concentrations of E2 and six concentrations of BPA (three replicates each treatment) 
were incubated with cells for 24 hours. The highest concentration of E2 (1×10-10 M) and 
BPA (5×10-7 M) were mixed with 10 nM ER inhibitor (ICI 182,780) to co-incubate with 
cells, also for 24 hours. Cells were washed with PBS once before being trypsinized and 
transferred into 1.5 ml eppendorf tubes. 1000 µL of culturing media was added into each 
tube to stop the trypsin activity. Samples were centrifuged at 3000 rpm for 5 minutes and 
the supernatant was discarded. 150 µL of PBS was added into each tube to resuspend 
cells into solution. 350 µL of EtOH was added to stabilize cells at 4°C for two hours. 
Cells were then centrifuged again to discard the supernatant before staining with 
PI/RNAse mixed with PBS at 1:1. Flow cytometric measurements for cell samples were 
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performed using a LSRFortessa 3 Laser, HTS flow cytometer (BD Biosciences). The data 
was then analyzed using FlowJo 7.6 using Watson Pragmatic model for cell cycle 
analysis.   
 
	  
Figure 5.5. Response of different sensing systems (BenzNP-GFP sensor, Alamar Blue, 
and Hoechst 33342) with different cell numbers from 2k to 10k MCF-7 cells. BenzNP-
GFP complex is more sensitive to cell numbers than Alamar Blue and Hoechst 33342.  
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CHAPTER 6 
SENSING BY SMELL: NANOPARTICLE-ENZYME SENSORS FOR RAPID 
AND SENSITIVE DETECTION OF BACTERIA WITH OLFACTORY OUTPUT 
 
6.1. Abstract 
 
 We present here a highly efficient sensor for bacteria that provides an olfactory 
output, allowing detection without the use of instrumentation, and with a modality that 
does not require visual identification. The sensor platform uses nanoparticles to 
reversibly complex and inhibits lipase. These complexes are disrupted in the presence of 
bacteria, restoring enzyme activity and generating scent from odorless pro-fragrance 
substrate molecules.  This system provides rapid (15 min) sensing and very high 
sensitivity (102 cfu/mL) detection of bacteria using the human sense of smell as an 
output. 
 
6.2. Introduction 
 
The human olfactory system has evolved to detect extremely low concentrations 
of volatile organic compounds present in complex environments.1  Humans can 
discriminate more than 1 trillion olfactory stimuli, several orders of magnitude greater 
than their capability in visual discrimination.2  This sensitivity and versatility makes 
olfaction a promising platform for biotechnological applications,3 however there have 
been few examples of the application of translation of sensor responses to olfactory 
outputs. 4-7 
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Figure 6.1. Schematic representation of sensor elements used in this study.  Cationic 
AuNPs bind with the anionic enzyme inhibiting the catalysis of the pro-fragrance into 
scent.  Bacteria present in solution compete for the AuNP surface and displace the 
enzyme inducing the production of the rose fragrance. 
 
Nanotechnology provides new opportunities to redefine the bounds of human 
perception.8  There have been a wide variety of examples where the intrinsic properties of 
nanomaterials have been used to generate visual output,9,10 with additional examples of 
nanomaterials modulating other colorimetric processes.11-13 Engineered nanomaterials 
have also been shown to influence the behavior of fragrance molecules.14  In a recent 
study, Weder et al. demonstrated cellulose nanocrystals functionalized with pro-fragrance 
molecules that could be used to control the production of volatile compounds.4 These 
covalently bound complexes remain odorless until functional groups are cleaved in 
response to specific external stimuli, generating pungent aroma molecules.5 Taken 
together, we hypothesized that pro-fragrances in combination with surface-engineered 
nanomaterials could provide reactive constructs to transduce molecular interactions into 
outputs that could be ‘read out’ through our sense of smell, providing a useful sensor 
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modality for detection of bacteria that provides a potential strategy for combatting the 
threat of bacterial drinking water contamination that contributes to over 1.5 million 
deaths worldwide a year.15,16      
We use a supramolecular-based approach to generate an effective smell-based 
sensor platform for bacteria. The system is comprised of three tunable components: 1) 
surface functionalized gold nanoparticles (AuNP), 2) pro-fragrance molecules, and 3) 
enzymes to cleave the pro-fragrances to generate the olfactory output (Figure 6.1).  In this 
sensor, the surface moieties of the nanoparticles behave as both selective recognition 
elements for analytes present in solution and to reversibly inhibit the complexed 
enzymes.13 The pro-fragrance molecules17 provide a ‘turn-on’ response for the sensor 
system, going from odorless to strongly odiferous upon cleavage by the enzyme. Finally, 
the enzyme provides a strategy for amplifying the output, generating multiple fragrance 
molecules per recognition event.18 Bringing these components together provides a 
sensitive sensor system for bacteria, allowing human subjects to rapidly detect bacteria in 
solution at levels as low as 102 cfu/mL, a relevant limit of detection for overall bacterial 
load in drinking water, and consistent with other recently published sensor systems.19-22 
 
6.3. Results and Discussion 
 
Our sensor design uses nanoparticles to both recognize the bacteria and to inhibit 
the fragrance-generating enzyme. We chose AuNPs possessing ligands with terminal 
benzyl headgroups, as these nanoparticles have been shown to interact strongly with the 
anionic cell surface of bacteria. 23,24 We used the robust and industrially used Candida 
Rugosa lipase as the enzymatic amplifier, 25 relying on the negative charge of the protein 
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to provide electrostatic complementarity with the cationic nanoparticle, and hence 
inhibiting catalysis.11,26,27  Given the ability of human olfaction to discern an enormous 
variety of scents, we had a wide range of pro-fragrance options to choose from. We 
ultimately chose the succinic acid ester of phenylethyl alcohol (SAEPE) as our 
substrate/pro-fragrance, due to the low odor threshold of phenylethyl alcohol,28 coupled 
with the orthogonality of the pleasant rose scent with odors commonly found in 
contaminated drinking water. 
	  
Figure 6.2. Lipase inhibition assay in the presence of benzyl AuNP. Lipase (15 nM) was 
incubated with a series of benzyl AuNP concentrations before adding the colorimetric 
substrate p-NPB (0.6 mM).  
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We initially performed a colorimetric assay to optimize the AuNP:lipase ratio 
required for inhibition.  These studies were performed using p-nitrophenylbutyrate 
(pNPB) in sodium phosphate buffer solution (5 mM, pH 7.4). As shown in Figure 6.2, an 
approximately 3:1 AuNP to lipase ratio provided essentially complete inhibition of the 
lipase.  This AuNP:lipase ratio was used to generate the nanozyme complex for all 
further studies. This colorimetric assay was able to detect both Gram positive and 
negative bacteria, including: E. coli, B. subtilis, M. luteus, and P. aeruginosa (Figure 
6.3), indicating the generality of the enzyme activation process.  
 
	  
Figure 6.3 Detection of bacteria using the nanozyme complex with colorimetric substrate 
p-nitrophenylbutyrate (pNPB) in sodium phosphate buffer solution (5 mM, pH 7.4). I0 is 
the initial absorbance of the nanozyme complex without bacteria and I is the final 
absorbance of the nanozyme complex in the presence of bacteria after 30 minutes of 
incubation. E. coli, B. sub, M. luteus, P. aeru.   
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We next turned to bacterial sensing using the enzyme platform, beginning with an 
instrument-based analytical strategy. These studies used E. coli as a non-pathogenic 
“safe” bacteria strain to minimize health concerns in both the instrumental and human 
studies.29  Solutions of the sensor elements were incubated for 30 minutes prior to the 
addition of the pro-fragrance.  We then used headspace gas chromatography to quantify 
the production of scent generated by our bacterial sensor.30  The concentration of the 
volatile product present in the headspace of the sample vial was quantified according to 
an external calibration curve (see Supporting Information).  As shown in Figure 6.4, the 
uninhibited lipase cleaves significantly more pro-fragrance than the nanoparticle-enzyme 
complex and controls. Significantly, no signal was observed using the substrate alone and 
bacteria, indicating that the bacteria do not hydrolyze the pro-fragrance in the timeframe 
studied.  As expected, the sensor system generated measurable and distinctly different 
signals in the presence of 104 and 106 cfu/mL of E. coli.  
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Figure 6.4. Headspace gas chromatography analysis of sensor response to increasing 
concentrations of bacteria.  Samples were prepared in triplicate.  Error bars represent 
standard deviations of the measurements.  *= p< 0.05, ***=p<0.001. 
 
 
Having established the generation of fragrance output, we next determined the 
ability of humans to serve as “detectors”. Ten volunteers were asked to smell glass vials 
at two time points: 1 minute as a control, and 15 minutes for sensing, with the interval 
chosen to ensure olfactory clearance.31 They ranked the samples in order from least/no 
smell (1) to strongest smell (5), and the raw ranking order data were analyzed using the 
Kruskal-Wallace H-test. Initial studies focused on the sensitivity of the scent response. 
As expected, participants were able to detect the phenylethyl alcohol at both time points 
(Figure 6.5a). In contrast, the enzyme-substrate pair was not detected at 1 minute, but 
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readily discerned at 15 minutes. In our sensing studies, no significant difference in 
response was observed across conditions at 1 minute under any conditions; however after 
15 minutes participants were successfully able to detect E. coli concentrations at both 102 
and 104 cfu/mL (Figure 6.5b) with high significance relative to the controls. Interestingly, 
102 cfu/mL of E. coli did not produce a detectable signal using gas chromatography, 
demonstrating that human olfaction was more sensitive than the chromatographic 
method.  
 
	  
Figure 6.5. Human olfactory detection studies. (a) Lipase activity test in the presence of 
the pro-fragrance SAEPE was carried out with six participants. SAEPE only and 5 mM 
Phosphate buffer were used as the negative control. The hydrolyzed form of SAEPE was 
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used as the positive control (strong standard). Hydrolyzed SAEPE and SAEPE in the 
presence of uninhibited lipase are significantly different from the negative controls 
SAEPE alone (p<0.01 and p<0.01, respectively) after 15 minutes. (b) With ten 
participants, olfactory detection of E. coli at 102 and 104 cfu/mL were compared to the 
controls of just buffer and sensor only after 15 minutes. The olfactory signals from the 
vials which contained 102 and 104 cfu/mL of E. coli are significantly different from the 
signal from the sensor-only vial (p<0.001 and p<0.0001, respectively).   
 
6.4. Conclusions  
 
In summary, we report here the development of a supramolecular-based sensor 
that uses the human olfactory system to read out the response.  This sensor was able to 
detect bacteria with high sensitivity. These studies demonstrate that by controlling the 
behavior of responsive nanomaterials at the molecular level, we can alter how human 
beings observe their surroundings in a manner that is otherwise impossible.  We believe 
this responsive strategy can be broadly applied to other surface functionalized 
nanoparticles and enzymes to provide sensing of a wide variety of analytes, with the 
availability of an almost limitless number of aroma profiles providing versatility 
unavailable with other transduction strategies. 
 
6.5. Experimental section 
 
6.5.1. Bacteria Growth Conditions. Bacteria were cultured in LB medium at 37 
°C and 275 rpm until stationary phase.  The cultures were then harvested by 
centrifugation and washed with 0.85 % sodium chloride solution for three times. 
Concentrations of resuspended bacterial solution were determined by optical density 
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measured at 600 nm. 5 mM sodium phosphate buffer was used to make dilutions of 
bacterial solutions.  
6.5.2. Plate Reader Assay. Lipase inhibition assay was done at 25 °C with the 
final concentrations in Costar clear 96 well plate of 15 nM lipase, 0.6 mM pNPB, and 20, 
40, 60, 80, 100 nM benzyl AuNP. Lipase and benzyl AuNP were first incubated for 30 
minutes in 96 well plate to insure their interaction reaches equilibrium, then 10 µL of 
substrate p-NPB was added into the well. The activity of lipase was monitored every 30 
seconds for a total of 40 minutes time frame at the absorbance of 405 nm.   
6.5.3. Human Trial Assays. 
Olfactory detection of lipase activity: Four different solutions were made in 20 
mL glass vials with a final volume of 1 mL each.  The volume of 1 mL was chosen to 
maintain the easy-to-use format of the sensor for eventual on-site detection use. 5 mM 
sodium phosphate buffer and 4 mM SAEPE were used as the negative controls and the 
rose scent (2-Phenylethyl alcohol) was used as the positive control, a strong standard. 
The activity of lipase was assessed by incubating 100 nM of lipase with 4 mM of SAEPE 
for 20 minutes. The participants were asked to smell these samples and rank them in the 
order from 1 to 5 with 1 has the lightest smell and 5 has the strongest smell.  
Olfactory detection to determine the threshold of phenylethyl alcohol: Serial 
dilutions of phenylethyl alcohol were prepared and detected by five volunteers to 
establish the threshold of the rose fragrance. ‘Yes’ indicates that the volunteer was able to 
smell the fragrance and ‘No’ indicates that no fragrance was detected. The threshold of 
phenylethyl alcohol detected by volunteers was determined to be in µM range, which is 
consistent with previous report (Table 6.1).28 
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Table 6.1. Serial dilutions of phenylethyl alcohol detected by five volunteers. 
Vial 
# Type 
Conc. 
(M) 1 2 3 4 5 
Percentage 
(%) 
1 Fragrance 0.05 Yes Yes Yes Yes Yes 100 
2 Fragrance 0.01 Yes Yes Yes Yes Yes 100 
3 Fragrance 0.005 Yes Yes Yes Yes Yes 100 
4 Fragrance 0.001 Yes Yes Yes Yes Yes 100 
5 Fragrance 0.0005 Yes Yes Yes Yes Yes 100 
6 Fragrance 0.0001 Yes Yes Yes Yes Yes 100 
7 Fragrance 0.00005 Yes Yes Yes Yes Yes 100 
8 Buffer 0 No No No No No 100 
9 Buffer 0 No No No No No 100 
 
Olfactory detection of E. coli: The same procedure was followed as above for 
buffer and sensor samples. For the E. coli-containing vials, 100 nM lipase was incubated 
with 300 nM benzyl AuNP for 30 minutes, and then 10 µL of E. coli was added into each 
vial so that the final concentrations of E. coli in each vial are 102 and 104 cfu/mL.  
6.5.4. Gas Chromatography Head-Space Analysis. Headspace phenylethyl 
alcohol was measured using a gas chromatography (model GC-17A, Shimadzu Co., 
Tokyo, Japan) equipped with a solid-phase microextraction (SPME) auto injector (model 
AOC-5000, Shimadzu Co., Tokyo, Japan).  Samples (1 mL) in 20 mL glass vials capped 
with aluminum caps with polytetrafluoroethylene (PTFE)/silicone septa.  Samples were 
prepared using 500 nM lipase, 1.5 µM benzyl AuNP, and 4 mM of SAEPE.  A 50/3 µm 
divinylbenzene (DVB)/carboxen/polydimethylsiloxane (PDMS) stable flex (SPME) fiber 
(Supelco Co., Bellefonte, PA) was then inserted into the vial headspace for 2 min to 
absorb volatiles.  The fiber was transferred to the GC injector port (250 °C) for 3 min.  
The injection port was operated in split mode, and the split ratio was set at 20:1.  
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Volatiles were separated on a fused-silica capillary Equity-1 Supelco column (30 × 0.25 
mm inner diameter × 25 µm) coated with 100% PDMS at an initial oven temperature of 
70 °C to final temperature of 220 °C over 10 min (step rate 15 °C/min).  A flame 
ionization detector was used at a temperature of 250 °C.  Phenylethyl alcohol 
concentrations were determined from peak areas using a standard curve made from 
dilutions of phenylethyl alcohol in 5 mM sodium phosphate buffer.  Each measurement 
was performed in triplicate and results were expressed as mean values ± standard 
deviation. 
6.5.5. Kruskal-Wallace H-test. Kruskal-Wallis test is a non-parametric version 
of one-way ANOVA which is applied when the assumption of normal (Gaussian) 
distribution is not met. This test can compare the medians of multiple samples to 
determine if they come from the same population or not. This methodology uses ranks of 
the data to compare the test statistics. To do so, the results from all groups are pooled and 
arranged in rank order from smallest to largest. The numeric index of this ordering is then 
used to evaluate the null hypothesis (sample are coming from the same distribution) using 
chi-square statistics. MATLAB software (MATLAB and Statistics Toolbox Release 
2012b, The MathWorks, Inc., Natick, Massachusetts, United States) was used to perform 
Kruskal-Wallis test.32,33  
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CHAPTER 7 
 
FUTURE TRENDS IN CHEMICAL-NOSE SENSING 
	  
Chemical-nose sensors have been proven to be an effective approach for complex 
mixture identification. This method truly shines when the knowledge of the biomarker in 
the mixture of interest is poorly characterized.  
For cancer diagnostic applications, chemical-nose sensors hold great promise to 
be transformed into useful point-of-care tests (PoC) due to their simplistic design and 
rapid detection capability. These features are desired for the development of PoC tests to 
meet the ASSURED guidelines established by the World Health Organization. PoC tests 
using chemical-nose approach are even more valuable in settings that have limited access 
to clinical facilities such as suburband areas, especially in developing countries. 
For environmental toxicity testing, chemical-nose sensors are the “first line of 
defense” as it can act as a primary screening tool to identify which compound or mixture 
can potentially pose a threat to humans and the environment. Using this approach, 
~72,000 uncatagorized compounds can be rapidly screened and narrowed down to the 
most harmful compounds, without the costly and time-consuming process such as the 
screening program assays established by the Environmental Protection Agency (EPA). 
Further testing is required to gain detailed insights about the mechanisms of action for 
these compounds or mixtures. In addition, many compounds are only toxic after being 
metabolized. Therefore, testing only the parent molecules can yield false negative results. 
To cover the wide range of toxicity, in-vivo tests are desirable. However, to reduce the 
cost, other in-vitro tests that can capture the metabolisms of compounds of interest are 
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more suitable for primary screening. These tests could potentially utilize liver cells or 
organ-on-the-chip technology to screen the metabolites of the parent compounds.  
Chemical-nose sensor demonstrated its usefulness in the bacterial detection 
application, where a general ‘yes’ or ‘no’ answer to the bacterial existence in drinking 
water is typically sufficient for in-the-field testing. However, if we want to extend the use 
of the chemical-nose sensing approach to other specific settings in bacterial detection 
such as food quality control, restaurants, and hospitals, more vigorous sensing tests need 
to be developed. These ‘nose’ tests should be more specific toward mixtures of bacteria 
in general, and not respond to any other analytes such as other food ingredients or 
sanitizing agents. For this purpose, ‘nose’ sensors are required to establish a base line 
describing the common background found in those specific settings. This is a requirement 
that is not essential for bacterial detection in drinking water due to its relatively simple 
environment (not many compounds or organisms exist in drinking water). 
Chemical-nose sensors offer a new pathway for point-of-care testing thanks to 
their simplistic design and relatively low-cost materials. However, to successfully 
implement this sensing approach for PoC testing, much more effort needs to be 
contributed in this field to increase the sample size and extend the analyte map. This will 
lead to big data trends in chemical-nose sensing, which requires more data scientists to 
validate ‘nose’ tests using appropriate statistical analysis, including machine learning 
approaches, something with which not all biologists and chemists are comfortable 
handling. Taken together, the success of ‘nose’ sensor in the PoC testing field will require 
the convergence of interdisciplinary knowledge in biology, chemistry and statistics. 
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Advances in pattern recognition sensing will then be truly transformative, making rapid 
and highly personalized diagnosis a reality.  
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